Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2016

An Injectable Stem Cell Delivery System for Treatment of
Musculoskeletal Defects
Shirae Leslie
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Biomaterials Commons, and the Chemical Engineering Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/4472

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

©

Shirae K. Leslie 2016
All Rights Reserved

An Injectable Stem Cell Delivery System for Treatment of Musculoskeletal Defects

A Thesis Submitted
in the Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy at
Virginia Commonwealth University

By

Shirae Kerisha Leslie
Master of Science in Biomedical Engineering, Georgia Institute of Technology, 2013
Bachelor of Science in Chemistry, Randolph College, 2009

Director: Dr. Barbara D. Boyan,
Dean
School of Engineering

Virginia Commonwealth University
Richmond, Virginia
February, 2016

ii

ACKNOWLEDGEMENTS

I would like to thank my parents Mr. and Mrs. D. Leslie whole heartedly for their
continuous support throughout my graduate studies, without them by my side I would not have
completed graduate school. My deepest gratitude goes toward my brother, one of my greatest
supporters and cheerleaders, giving me numerous motivational speeches along my graduate school
journey. To my remaining family members, I am very grateful for your various calls, and texts to
offer encouragement and prayers for the protection of my sanity. Thanks to my friends across the
globe with their never ending support, assuring me that the end is near. Chantel for her
encouragement, chocolates to fuel the late nights. I am very grateful for Debbie providing
encouragement and home cooked meals when I was not able to do so.
Dr. Boyan and Dr. Schwartz, thank you for your mentorship during graduate school and
taking your time to coach me in developing my scientific skills. Thanks for providing funding for
my graduate research as my thesis project developed and guiding me as I solved problems directly
related to my thesis work by thinking outside of the box. Thanks to my committee members who
have guided me in completing my thesis and played a major role in some experiments of the thesis.
Dr. Sundaresan, thank you for aiding and conducting the analysis of the migration study. I am
grateful for the support of the present and past members of the Boyan-Schwartz laboratory in
conducting experiments and troubleshooting various experimental problems. Thanks to Sharon
Hyzy for ensuring that all components of the experiments were ordered in a timely fashion. Thanks
to Dr. Cohen for aiding in the in vivo experiments, MicroCT and processing histological samples.
Thanks to my undergraduates Eric Pinsker and Nathan Kirby for their work on projects that

iii

contributed to the thesis. The remaining members of the laboratory thanks for helping with animal
surgeries and editing my written work.

iv

TABLE OF CONTENTS
Page

ACKNOWLEDGMENTS ........................................................................................................ iii
LIST OF TABLES ................................................................................................................... viii
LIST OF FIGURES ................................................................................................................... ix
LIST OF SYMBOLS AND ABBREVIATIONS ..................................................................... xi
ABSTRACT ............................................................................................................................... 14
CHAPTER
1

Specific Aims .......................................................................................................... 15

2

Background and Literature Review ..................................................................... 18
Bone ............................................................................................................. 18
Stem Cells and Fracture Repair .................................................................. 18
Non-unions .................................................................................................. 19
Stem Cells and Cartilage Repair.................................................................. 20
Therapies for Fracture Repair ...................................................................... 21
Cell-based Therapies for Fracture Repair.................................................... 21
Cell-based Therapies for Cartilage Repair .................................................. 23
Microencapsulating Stem Cells for Therapy ............................................... 23

3

Development of a Cell Delivery System Using Alginate Microbeads for Tissue
Regeneration ........................................................................................................... 27
Introduction ................................................................................................. 27
Methods ....................................................................................................... 30
Results ......................................................................................................... 38
v

Discussion ................................................................................................... 49
4

The Production of Osteogenic and Angiogenic Factors from Microencapsulated
ASCs is Species Dependent and can be Modified by the Pretreatment of Media
used .......................................................................................................................... 54
Introduction ................................................................................................. 55
Methods ....................................................................................................... 58
Results ......................................................................................................... 62
Discussion ................................................................................................... 71

5

The Development of a Degradable Alginate Microbead System for Bone
Regeneration ........................................................................................................... 75
Introduction ................................................................................................. 75
Methods ....................................................................................................... 78
Results ......................................................................................................... 86
Discussion ................................................................................................... 99

6

Microencapsulated rabbit ASCs support Chondrogenesis in a Rabbit Auricular
Defect Model ......................................................................................................... 106

Introduction ............................................................................................... 107
Methods ..................................................................................................... 108
Results ....................................................................................................... 117
Discussion ................................................................................................. 127

vi

7

Discussion .............................................................................................................. 131

REFERENCES ........................................................................................................................ 135
APPENDICES ...................................................................................................................... cxlvii

A.

Osteoinductive Nature of Microencapsulated ASCs ...................................... cxlvii
Introduction ............................................................................................ cxlvii
Methods ................................................................................................... cxlix
Results ........................................................................................................ clii
Discussion ................................................................................................ clvii

B.

Microencapsulated rASCs Support Osteogenesis in a Unicortical Diaphyseal
Defect ...................................................................................................................... clx

Introduction ................................................................................................ clx
Methods .................................................................................................... clxii
Results ...................................................................................................... clxv
Discussion .............................................................................................. clxvii

vii

LIST OF TABLES
Page
Table 3.1: Growth factor secreted in media and retained in the microbeads by microencapsulated
cells treated with chondrogenic media. .....................................................................41

Table 3.2: Effects of microbead number per well and number of cells per microbead on cell
viability……….……………………………………………………………………. 45

Table 4.1: Primer sequences used for the analysis of mRNA levels…………………………... 62
Table 5.1: Primer sequences used for the analysis of mRNA levels……………………………85
Table 6.1: Primer sequences used for the analysis of mRNA levels……………………..……111
Table 6.2: Microencapsulated rbASCs induced new tissue ………………………………. .... 120

viii

LIST OF FIGURES
Pages
Figure 2.1: Microencapsulated ASCs derived from rat and human……………………………24
Figure 2.2: Schematic of electrostatic potential based microencapsulation……………………25
Figure 2.3: Release of ASCs from alginate (medical grade) microbeads with different
formulations of alginate lyase (U): alginate (g) over a 12 day period……………...26
Figure 3.1: The diameter of alginate microbeads crosslinked in calcium chloride solutions
made with different osmolytes……………………………………………………. 39
Figure 3.2: Viability of microencapsulated rASCs crosslinked in calcium chloride solutions
made with different osmolytes……………………………………………………. 40
Figure 3.3: Effect of microbead density per unit volume on growth factor production
by microencapsulated hASCs……………………………………………………... 42
Figure 3.4: Effect of cell number per microbead on growth factor production by
microencapsulated hASCs………………………………………………………… 43
Figure 3.5: The effect of microbead density per well on cell release from microbeads………. 44
Figure 3.6: In Vivo localization of rASCs……………………………………………………... 46
Figure 3.7: Ex vivo organ assessment………………………………………………………….47
Figure 3.8: H&E staining of subcutaneous site of alginate microbead implantation
after 6 weeks……………………………………………………………………… 48
Figure 4.1: DNA content……………………………………………………………………….63
Figure 4.2: VEGF/FGF/BMP2 levels produced in the media by rASCs cultured on TCPS
and outside microencapsulated rASCs…………………………………………….64
Figure 4.3: VEGF/FGF/BMP 2 levels produced within microbeads………………………….66
Figure 4.4: mRNA levels of Vegfa/Fgf2/Tgfβ1 in rASCs cultured on TCPS and
microencapsulated rASCs…………………………………………………………67
Figure 4.5: mRNA levels of Vegfa/Fgf2/Tgfβ1 in rASCs cultured on TCPS and
microencapsulated rASCs…………………………………………………………68

ix

Figure 4.6: VEGF and BMP2 levels produced in the media by microencapsulated rASCs,
mASCs, rbASCs and hASCs…………………………………………….………70
Figure 5.1: Degradation of alginate (wound healing grade) microbeads with different
formulations of alginate lyase (U): alginate (g).of alginate microbeads crosslinked
in calcium chloride solutions…………………………………………………..….87
Figure 5.2: Degradation of alginate (medical grade) microbeads with different formulations of
alginate lyase (U): alginate (g).in calcium chloride solutions………………….….89
Figure 5.3: Release of ASCs from alginate (medical grade) microbeads with different
formulations of alginate lyase (U): alginate (g) over a 12 day period…………....91
Figure 5.4: Release of GFP-conjugated ASCs and MG63 osteoblast-like cells from alginate
(medical grade) microbeads with different formulations of alginate lyase (U):
alginate (g) over 12 days…………………………………...………………….…92
Figure 5.5: The diameter of alginate microbeads crosslinked in calcium chloride solutions
made with different osmolytes……………………………………………….…..93
Figure 5.6: Viability of ASCs in microbeads without alginate lyase………………………...94
Figure 5.7: Viability of ASCs released from alginate (medical grade) microbeads made with
different formulations of alginate-lyase (U): alginate (g)…………………….….96
Figure 5.8: The osteogenic potential of ASCs released from alginate microbeads…………..97
Figure 5.9: mRNA expression in ASCs released from alginate microbeads………………....99
Figure 6.1: Schematic outlining the experimental method……………………………...…...115
Figure 6.2: Multipotency of rbASCs………………………………………………………...118
Figure 6.3: Phenotype of rbASCs after microencapsulation………………………………...119
Figure 6.4: Critical size defect in auricular cartilage…………………………...……….......120
Figure 6.5: MicroCT analysis of tissue in defects at 12 weeks post surgery………………..121
Figure 6.6: Defects after 12 weeks…………………………………………………..……...122
Figure 6.7: Defects filled with degradable microbeads incorporating rbASCs………..…....123
Figure 6.8: Elastin staining of cartilage…………….......…….……….…………....……......124
Figure 6.9: Histomorphometric Analysis……..……………….……….…………....…….....125
Figure A.1: H&E staining of DBM implanted in male White New Zealand rabbits after 6
weeks……………………………………………………………………….…..cliii
x

Figure A.2: H&E staining of microbeads in rabbits after 6 weeks……………………….....cliii
Figure A.3: Volume of radio-opaque tissue from micro CT analysis…………………..…...cliv
Figure A.4: H&E staining of DBM implanted in male athymic nude mice after 8
weeks…………………………………………………………………………....clv
Figure A.5: H&E staining of rASC osteoinductivity in athymic nude mice after 8
weeks…………………………………………………………………….….…..clv
Figure A.6: H&E staining of mASC osteoinductivity in athymic nude mice after 8
weeks…………………………………………………………………..……....clvi
Figure A.7: Area of adipose tissue after microencapsulated mASCs were implanted in
gastrocnemius of mice for 8 weeks………………………………………...….clvii
Figure B.1: H&E staining of the defect site in the femur after 8
weeks……………………………………………………………….…………clxvi
Figure B.2: H&E staining of unicortical defects receiving non-degradable microencapsulated
rASCs………………………………………………………………………...clxvii
Figure B.3: Histomorphometric analysis of cortical bone, trabecular bone and marrow cavity
of the unicortical diaphyseal defect after 8 weeks……..……………………clxviii

xi

LIST OF SYMBOLS AND ABBREVIATIONS
ACAN

Aggrecan

AM

Adipogenic differentiation medium

ANOVA

Analysis of Variance

BMP2

Bone morphogenetic protein 2

CM

Chondrogenic differentiation medium

Col 1

`

Collagen Type I

Col 2

Collagen Type II

Col 10

Collagen Type X

DiR

1,1’-dioctadecyltetramethyl indotricarbocyanine iodide

DMEM

Dulbecco’s modified Eagle’s medium

FBS

Fetal Bovine Serum

FGF

Fibroblast Growth Factor

GFP

Green Fluorescent Protein

HBSS

Hanks Balanced Salt Solution

IGF-1

Insulin-like Growth Factor

LEPR

Leptin receptor

MicroCT

Micro computed tomography

MG-63

Human osteosarcoma cell line

MSCGM

Mesenchymal Stem Cell Growth Medium

OCN

Osteocalcin

OM

Osteogenic Differentiation Medium

OPG

Osteoprotegerin

xii

Osx

Osterix

PBS

Phosphate Buffered Saline

PCR

Polymer Chain Reaction

PLGA

Poly-lactide co-glycolide

PPAR-γ

Peroxisome proliferation-activated receptor gamma

rASCs

Rat Adipose Derived Stem Cells

RUNX2

Runt-related Transcription Factor 2

TGFβ-1

Transforming growth factor beta 1

TGFβ-2

Transforming growth factor beta 2

TGFβ-3

Transforming growth factor beta 3

TUNEL

Terminal Deoxynucleotidyl Transferase Nick-End
Labeling

VEGF

Vascular endothelial growth factor

xiii

ABSTRACT
AN INJECTABLE STEM CELL DELIVERY SYSTEM FOR TREATMENT OF
MUSCULOSKELETAL DEFECTS
By
Shirae K. Leslie, M.S.
A Thesis Submitted to in the Partial Fulfillment of the Requirements for the Degree Doctor of
Philosophy at
Virginia Commonwealth University 2016
Director: Dr. Barbara D. Boyan, Dean, School of Engineering
Virginia Commonwealth University

The goal of this research was to develop a system of injectable hydrogels to deliver stem
cells to musculoskeletal defects, thereby allowing cells to remain at the treatment site and secrete
soluble factors that will facilitate tissue regeneration. First, production parameters for
encapsulating cells in microbeads were determined. This involved investigating the effects of
osmolytes on alginate microbead properties, and the effects of alginate microbead cell density,
alginate microbead density, and effects of osteogenic media on microencapsulated cells. Although
cells remained viable in the microbeads, alginate does not readily degrade in vivo for six months.
Therefore, a method to incorporate alginate lyase in microbeads was developed and optimized to
achieve controlled release of viable cells. Effectiveness of this strategy was determined through
cell release studies and measuring proteins and expression of genes that are characteristic of the
cell’s phenotype. Lastly, in vivo studies were done to assess the ability of alginate microbeads to
localize microencapsulated cells and support chondrogenesis and osteogenesis. This project will
provide insight to the tissue engineering field regarding cell-based therapies and healing
musculoskeletal defects.
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CHAPTER 1

Specific Aims
57 million musculoskeletal injuries occur each year, of which 26% are fractures [1]. Five
to 20% of the total fractures result in nonunion [1]. A fracture results in non-union when the bone
fails to heal completely with bone. Despite the prevalence of fractures resulting in non-unions,
there are no methods that currently exist to prevent their occurrence.
Cartilage injuries can occur in ear, nose, and areas articulating joints. In addition, there is
a high demand for cartilage replacement in musculoskeletal diseases and congenital birth defects.
Unlike bone, cartilage is avascular and tissue regeneration is difficult to achieve.
For defects in both tissue types, current therapies include a surgical procedure involving
the implanting of a cell-laden scaffold, an allograft, or a biomaterial. However, these therapies do
not lead to total repair due to the inability for the delivered cells or biomaterial to integrate
completely. In addition, donor site morbidity may limit the number of autologous cells available,
necessitating the use of allogeneic cells, which may be rejected by the host. Injectable cell-based
therapies would be especially advantageous for these patients since it’s less invasive and possess
the potential to have greater success.
Cell-based therapies using adipose-derived stem cells (ASCs) provide one possible form
of treatment for bone defects. ASCs are known to be multipotent [2], easily isolated, and readily
available. One disadvantage of cell-based therapies is cells tend to disperse to other tissues [3]. It
is critical that a method of delivery is developed to allow cells to remain at the injury site, maintain
their ability to differentiate and release cells after a given period. One option is to use alginate, a
15

well-known biocompatible hydrogel. Alginate is known to maintain cell viability after injection
and thus could be used as a delivery platform [4, 5]. In addition, alginate provides a system that
allows for the exchange of nutrients, wastes and secreted factors. However, alginate does not
readily degrade in vivo for six months. Therefore before it can be used to deliver cells, a method
of controlled degradation must be established. Prior to this research, there were no methods to
control the degradation of alginate hydrogels in vivo. Several attempts have been made by using
gamma irradiation, oxidization and a bifunctional crosslinker, however they have not been
successful [6, 7]. The objective of this project was to develop an injectable stem cell delivery
technology for treatment of musculoskeletal defects.
Specific Aim 1: Determine production parameters for encapsulating stem cells in
injectable alginate microbeads.
Task 1.1 Determine the effects of osmolytes on alginate microbead properties.
Task 1.2 Determine the effects of alginate microbead cell density and alginate microbead density
on microencapsulated cells.
Task 1.3 Determine the effects of osteogenic media on microencapsulated cells.
Specific Aim 2: Develop a method of achieving a controlled release of rASCs from
alginate microbeads.
Task 2.1 Develop and optimize a method of incorporating alginate lyase in alginate microbeads.
Task 2.2 Establish degradation parameters to achieve controlled release of cells.
Task 2.3 Determine the viability of rASCs released from alginate microbeads.
Task 2.4 Determine the effect of alginate degradation on the phenotype of released rASCs.
Task 2.5 Investigate the ability of alginate microbeads incorporating alginate lyase to degrade in
vivo without an inflammatory response.
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Specific Aim 3: To determine the ability of alginate microbeads to localize cells at the site
of interest and support chondrogenesis and osteogenesis.
Task 3.1 Investigate the ability of alginate microbeads to localize cells.
Task 3.2 Determine the ability of microencapsulated rASCs to produce ectopic bone in vivo.
Task 3.3 Determine the ability of microencapsulated rASCs to regenerate bone in a unicortical
diaphyseal defect.
Task 3.4 Illustrate the multipotency of rbASCs.
Task 3.5 Demonstrate the ability of rbASCs to initiate cartilage regeneration.
Locally treating defects with injections provides a less invasive repair method than surgical
interventions for treating skeletal injuries. The use of these injectable hydrogels to deliver stem
cells will improve the success of cell-based therapies.
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CHAPTER 2

Background and Literature Review

2.1 Bone
Bone is a major organ in the body and a major part of the skeletal system. Over 200 bones
are present in the human skeletal system. Bone is a tough supporting tissue that functions in both
movement and structural stability in conjunction with muscles [8]. Bone is a dynamic tissue, which
includes a mineralized matrix embedded with blood vessels, bone cells, and nerves. There are three
types of bone specific cells – osteocytes, osteoblasts, and osteoclasts. Osteocytes sense mechanical
stress and send signals to osteoblasts for bone remodeling. Osteoblasts are able to secrete collagen
rich extracellular matrix that enables mineralization. Osteoclasts are responsible for bone
remodeling by localized acidification and protease secretion. Bone is formed by endochondral
ossification or intramembranous ossification. In endochondral ossification, cartilage is formed first
by mesenchymal progenitor cells differentiating to chondrocytes. Chondrocytes go through
hypertrophy and the extracellular matrix mineralizes. The invasion of blood vessels delivers cells
that degrade the extracellular matrix and osteoprogenitor cells to form bone. Intramembranous
ossification occurs directly where osteoprogenitors form bone directly. Long bones (femur, tibia)
are formed by endochondral ossification while flat bones (bones of the skull) are formed by
intramembranous ossification.

2.2 Stem Cells and Fracture Repair
Fracture repair is controlled by an appropriate cellular response and fracture mechanics,
which include how much the ends of the bone can move relative to each other (stable or unstable).
18

There are three phases of fracture repair; inflammation, reparative and remodeling. During the
acute period of fracture healing, inflammation leads to the release of bone-derived growth factors.
These growth factors contributes to the chemotaxis and aggregation of mesenchymal stem cells
(MSCs) to form a repair tissue known as a repair blastema. Acute inflammation results in
vasodilation and exudation of plasma and leukocytes. Inflammatory cells begin debris removal. In
the reparative phase, an increased cell division occurs first in the periosteum and tissues
immediately surrounding it and later extends throughout the fractured bone [9]. A mechanically
stable fracture has vasculature spanning the repair blastema and MSCs will differentiate into
osteoblasts to form woven bone, which later becomes remodeled. In the case of mechanically
unstable fractures, MSCs congregate in the repair blastema and form cartilage, which spans the
gap thereby providing flexible stability. Simultaneously, MSCs from the periosteum will produce
subperiosteal bone, which forms an outer bridge between the two ends of the fracture thus
providing more stability. At this stage, the cartilage starts to undergo hypertrophy, veins begin to
invade delivering resorptive elements to the hypertrophic cartilage and MSCs on the surface of the
hypertrophied and resorbing cartilage. In the presence of the new vasculature, MSCs undergo
osteogenic differentiation and new bone spicules are laid down to replace the cartilage. This
cartilage is replaced by woven marrow filled bone, which undergoes remodeling to become
cortical bone concluding the remodeling phase [10].

2.3 Non-unions
Long bone fractures are typically difficult and slow to heal (the initial bridging process)
primarily due to the lack of establishing an intact bony bridge between the fragments and providing
mechanical stability [9]. A rate of 5-10% of bone fractures result in the formation of a non-union.

19

A normal fracture heals within 6 to 8 weeks. Fractures in bones with thicker cortices may need a
few additional weeks to heal. However, if no healing occurs after 6 months it can be considered a
non-union. There are two types of non-unions: hypertrophic and atrophic non-unions. A
hypertrophic non-union has a large broadened callus that is not capable of regenerating a bony
union. The underlying reason for the hypertrophic non-union is the instability of the fracture,
which allows multidirectional motion of the fracture fragments. An atrophic non-union is
completely different. The underlying reasons for an atrophic non-union is a combination of
biological impairment and mechanical factors. The impaired biological factors include damaged
vascular supply and the destruction of the periosteum and endosteum. This impairment is also
coupled with soft tissue damage and detraction of the surrounding tissue. The mechanical
underlying reasons for atrophic non-unions include rigid fixation, insufficient compressive forces,
and a fracture gap that is too wide for a bony bridge to be formed [10].

2.4 Stem Cells and Cartilage Repair
Tissues that are continuously being remodeled like bone and liver, easily heal unlike other
tissues that do not constantly replace themselves. Complete repair of all types of cartilage is rarely
seen. There are three types of cartilage - hyaline cartilage, elastic cartilage and fibrocartilage.
Hyaline cartilage covers the bone in joints, elastic cartilage is present in the epiglottis and ear,
while fibrocartilage is found between the discs in the spine and between the bones of the hips and
pelvis. Once there is a lesion or break in the cartilage, there is no immediate presence of bioactive
factors and stem cells. Instead, for cartilage damage that does not go all the way to the underlying
bone, the cartilage rarely repairs. In contrast, in a full thickness cartilage injury, blood from the
underlying bone marrow fills the injured site carrying osteochondrprogenitor cells, which forms
fibrocartilage and restores the underlying bone [11].
20

2.5 Therapies for Fracture Repair
The gold standard for bone repair is using an autologous bone graft. The graft can take the
form of cancellous or cortico-cancellous bone, and may include vasculature. In addition,
osteoinductive materials like demineralized bone matrix (DBM) or osteoconductive synthetic
materials can be used. Exogenous growth factors can supplement any deficiency of endogenous
factors at the fracture site.
In cases where current bone graft substitutes fail, other interventions must take place.
Primary intervention fails sometimes because of a lack of host stem cells or compromised health
of the host. In some cases, implants can be used with modified surfaces to ensure that the bone
integrates well. Alternatively, implanting scaffolds that allow cell invasion and proliferation as
well as aiding in the regeneration process can be ued [12]. These scaffolds may or may not be
previously seeded with cells. In the cases where cell insufficiency is a problem, cell-based
therapies would be an appropriate solution.

2.6 Cell-based Therapies for Fracture Repair
Cell-based therapies for bone repair are beneficial for patients where there is a diminished
pool of progenitor cells or the host tissue is compromised [1]. There are many clinical trials
underway to investigate the efficacy of cell-based therapies for bone regeneration and repair. These
trials may take three forms – a cell suspension, a cell suspension coupled with a biomaterial or a
cell suspension with a biomaterial previously conditioned in a non-bony site. For the clinical trials
with cells only, stem cells may be derived from the bone marrow or adipose tissue. However very
little success has been seen the injection of stem cells intravenously or directly to the defect site.
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Most cells tend migrate to the lung [13]. Alternatively, some scientists have taken the approach of
delivering a concentrated mass of cells solely or combined with platelet rich plasma [14].
To achieve optimum results using cell suspensions, the cell suspension must be coupled
with a scaffold. Cell-based therapies have coupled cells with cancellous bone, platelet gel, β-tricalcium phosphate, calcium sulfate, DBM, collagen matrix or hydroxyapatite, as examples [14].
The results from these studies have shown greater bone formation with the presence of cells. In
fact, tricalcium phosphate and hydroxyapatite loaded with rat MSCs placed within a segmental
defect showed more radio opaque tissue within the defect compared to the scaffold alone [15]. For
trials with animals, the scaffold is sometimes loaded with cells and cultured in a muscle or
bioreactor for few weeks and later transplanted to an orthotopic site. This approach has led to good
results.
A number of different types of cells have been delivered to bone sites including:
unfractionated bone marrow stem cells, mesenchymal stem cells, differentiated osteoblasts or
chondrocytes, or genetically modified cells [16]. Hydroxyapatite loaded with culture expanded
progenitor cells was implanted in diaphyseal defects within humans. Most patients healed well
with good integration of the implant into the bone and regained functionality [17]. Other human
trials reporting the use of bone marrow-derived multipotent cells with macro-porous
hydroxyapatite scaffolds were placed within defects. The results showed the progressive
integration of implants in addition to more bone being present on the external surface. After a 7
year follow up a good integration of the implants were observed [18]. Most of the clinical trials
investigating cell-based therapies for fractures have employed bone marrow derived mesenchymal
stem cells. To date, results have shown the safety and effectiveness of the approach, however to
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get the optimum results it is still unknown how many progenitors from the bone marrow are needed
and raises the question if there is a large enough supply.

2.7 Cell-based Therapies for Cartilage Regeneration
There have been previous studies using cells for cartilage regeneration in animal models.
However most studies have focused on hyaline cartilage where MSCs have been combined with
biomaterials like polycaprolactone, polylactic acid, PLGA or fibrin gel. The results showed no
adverse effects and some repair of the cartilage within osteochondral defects. Additional studies
need to be carried out to determine if the new cartilage was indeed from the cells delivered. There
is no evidence in literature that this approach has been used for elastic cartilage however studies
have initiated that path for auricular cartilage by showing the presence of stem cells in the
perichondrium [19].

2.8 Microencapsulation of Stem Cells for Therapy
The therapeutic nature of stem cells derives from their ability to self-renew as well as
maintain the ability to differentiate along various lineages. In addition to differentiating into tissue
specific cells and contributing directly to tissue repair, stem cells can create a microenvironment
to support the regeneration of tissues or organs by secreting factors that elicit a regenerative
response from surrounding cells. Both of these roles require stem cells to be delivered to the
desired site and to remain at the site long enough to achieve the therapeutic goal.
The most common method of delivery is to infuse a stem cell suspension via the vasculature
[20]. Even when cell suspensions are injected directly to the intended site, most of the cells are
gone within 24 hours. There are a number of reasons for this, including cell migration and necrosis
resulting from the harsh environment. Additionally, the host’s immune system may reject the
23

newly introduced stem cells. A delivery system that shields and creates a temporary home for the
cells can improve their viability and increase their residence time at the delivery site.
Porous polymer hydrogels like alginate and gelatin have been used as cell-delivery vehicles
for some time [21]. Cells can be incorporated into the gels by simple dripping, vibration assisted
dripping, and emulsion based encapsulation [22]. These methods result in microbeads that are
generally about 500 µm in diameter. Microbeads of this size can limit the exchange of nutrients
and waste products and may not be injectable. To overcome these limitations, we developed an
electrostatic encapsulation method that results in microbeads that are 200 µm in diameter, are
easily injectable, and do not have reduced diffusivity of nutrients and waste products [23].
Alginate is an accessible, block co-polymer that consists of pure mannuronic acid (M)
blocks or pure guluronic acid (G) blocks, or alternating MG blocks [24]. Due to its ability to
instantaneously crosslink after exposure to divalent cations, alginate is used as a hydrogel. We
have successfully produced microbeads using a variety of alginate formulations including: high
mannuronate content alginate with low, medium and high viscosities [23] (Fig. 2.1).

Figure 2.1: Microencapsulated ASCs derived from (A) rat and (B) human.

Here we report the microencapsulation of cells using low viscosity, high mannuronate
content alginate. The crosslinking solution contains calcium chloride and glucose and is buffered
using 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Calcium chloride provides
24

divalent cations to crosslink alginate between mannuronate residues. Glucose is added as nutrient
osmolyte in order to maintain physiological osmolality of the crosslinking solution for the cells,
thus enabling reduced Ca++ content and enhancing cell viability [23]. HEPES prevents in vivo
calcification by maintaining pH at or below pH 7.3 (Fig. 2.2) [5]. This method produces
microbeads with a high surface area to volume ratio, which is beneficial for molecular transport.
Using this method adipose stem cells (ASCs) retain high viability during microencapsulation and
remain viable for up to 3 weeks in culture [5].

Figure 2.2: Schematic of electrostatic potential based microencapsulation.
Depending on the desired therapeutic use of the microencapsulated cells, the residence time
for cells within the microbeads may vary. In order for this to be possible the material used to
encapsulate the cells must be able to undergo controlled degradation in vivo. For example, a nondegradable polymer can be used if the therapeutic use of microencapsulated stem cells is insulin
production in the case of diabetic patients [25]. A degradable polymer can be used if it is required
for the stem cells to be released to support tissue regeneration. To control the rate of cell release,
we have developed a method by which the degradation of alginate can be modulated enzymatically
(Fig. 2.3). Alginate lyase cleaves the glycosidic bonds in alginate specifically between the
mannuronate and guluronate residues through a β-elimination reaction [26].
25

1.75 U/g

1.75 U/g

Figure 2.3: Release of ASCs from alginate (medical grade) microbeads with different
formulations of alginate lyase (U): alginate (g) over a 12 day period.
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CHAPTER 3

Development of a Cell Delivery System Using Alginate Microbeads for Tissue
Regeneration

Summary
Alginate microbeads incorporating adipose-derived stem cells (ASCs) have potential for
delivering viable cells capable of facilitating tissue regeneration. These microbeads are formed in
calcium crosslinking solutions containing organic osmolytes to ensure physiological osmolality,
but the comparative effects of these osmolytes on the microencapsulated cells are not known. In
addition, delivery parameters needed to use microencapsulated cells for tissue regeneration remain
unknown. We investigated the following parameters: 1) osmolyte effects on microbead diameter,
cell viability and growth factor production; 2) the effect of the number of cells per microbead and
the number of microbeads per unit volume on cell viability, growth factor production, and
microbead degradation; 3) the ability of both degradable and non-degradable alginate microbeads
to localize cells at the delivery site in vivo; and 4) whether alginate microbeads containing alginatelyase elicit an inflammatory response after repeated exposure. Smallest microbead diameters were
achieved using glucose as the osmolyte but cell viability and growth factor production did not
depend on osmolyte type. As cell number per microbead or microbead number per well increased,
growth factor production per cell decreased although percent cell viability was unchanged. The
rate of cell release varied with the number of beads per well and with the number of cells per
microbeads. At the highest microbead density and at the lowest density of cells per microbead, cell
release was delayed. Therefore fewer microbeads may be sufficient for clinical applications. Both
degradable (0.22 U/g) and non-degradable (0 U/g) alginate microbeads localized cells at the
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delivery site. Degradable alginate microbeads delivered subcutaneously elicited a mild chronic
inflammatory response on second exposure, but how this might impact repeated use of the
technology remains to be determined.
3.1 Introduction
Optimized production and delivery parameters for cell-based therapies are critical to their
regenerative capability. One goal for cell-based therapies is to use the minimal number of a
patient’s cells while maintaining cell viability, phenotype and function. For some cell-based
therapies it is important that the cells remain at the treatment site and that the material used as the
delivery vehicle does not have an adverse effect on the surrounding tissue or elicit an inflammatory
response.
We have shown that adipose-derived stem cells (ASCs) can be encapsulated in alginate
microbeads and remain viable for at least three weeks in culture [4]. Alginate is a block co-polymer
consisting of mannuronic acid, guluronic acid or alternating mannuronic and guluronic blocks
[27]. A hydrogel is formed instantaneously once alginate is exposed to divalent cations by forming
ionic bonds between the divalent cation and guluronic acid. Alginate hydrogels have been used in
a variety medical applications to deliver therapeutic agents and to encapsulate cells to deliver
endogenous proteins or aid in tissue regeneration and organ repair [28-30]. Typically, these
microbeads have diameters of 500µm or more [31]. By generating microbeads using an
electrostatic potential, 200µm diameters can be achieved, enabling the microbeads to be injected
through 18 gauge needles and facilitating greater mass transport of nutrients and waste [32].
Subsequent studies showed that these smaller beads necessitated reduced Ca++ content in the
crosslinking solution than is commonly used to generate the larger diameter microbeads to
preserve cell viability during the crosslinking process. To maintain osmolality of the cross-linking
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solution at physiological range, the nutrient glucose was included as an osmolyte [23]. However
whether other organic osmolytes could be used was not known, nor was it known what effect these
osmolytes might have on the beads themselves or on ASCs within the microbeads. The presence
of a nutrient osmolyte in the crosslinking solution also serves as an energy source, which can affect
the production of growth factors by the encapsulated cells. Therefore, one goal of the present study
was to compare the effects of glucose on microbead diameter as well as on cell viability and growth
factor production with those of two non-nutrient sugar osmolytes, mannitol and trehalose, and an
inorganic osmolyte - sodium chloride.
The number of cells required to achieve a therapeutic outcome is not known. Some studies
have shown that using a high cell dose leads to favorable response while the opposite has also been
observed [33]. The number of cells per microbead can be varied by altering the number of cells in
the original suspension, but how this might impact the overall viability of the cells or the
production of therapeutic factors per bead is not known. Moreover, it is not known whether the
number of beads per unit volume can affect these parameters. Finally it isn’t known if the release
of cells from the beads is affected by either the number of cells per bead or the number of beads
per unit volume.
Alginate microbeads can be injected directly to the desired treatment site and retain cells
at the site for at least 3 months [4]. Although alginate stability eventually decreases as Ca++ ions
diffuse from the hydrogel, this can occur much slower than tissue regeneration requires. Recently
we showed that alginate lyase can be used to provide controlled degradation of the hydrogel [34].
Here, we compared the ability of alginate microbeads that contain alginate lyase to localize rASCs
within tissue with alginate microbeads that do not contain the enzyme. Finally, we examined
whether the alginate lyase microbeads elicit an acute inflammatory response typical of many
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biomaterials [35] or if they elicit a delayed hypersensitivity reaction. This is important because
ultrapure alginate is not known to elicit an inflammatory response in vivo. However it is unknown
if the by-products of alginate lyase mediated digestion elicit an inflammatory response.
This study explores production and delivery parameters for microencapsulated ASCs. Cellbased therapies should be efficient in using the minimum number of cells required to achieve
regeneration, especially in cases where availability of autologous cells is low.
3.2. Methods
3.2.1 Adipose Derived Stem Cells
ASCs were isolated from six 100-125g male Sprague-Dawley rats under an Institutional
Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute of
Technology and Virginia Commonwealth University and cultured using a previously described
method [2, 36]. Briefly, the inguinal fat pad was removed and transferred to a container with
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3%
sterile-filtered L-glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with
Hank’s balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) (Sigma Aldrich, St. Louis, MO) for 30 minutes on a
rocker at 37°C. Following trypsinization, the supernatant was discarded. Adipose tissue was cut
into small pieces and incubated in a digestive cocktail containing collagenase type I (365 units/mL)
(Sigma Aldrich) and dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours. After incubation,
the oily upper layer was removed and the digest was quenched with an equal amount of
mesenchymal stem cell growth medium (MSCGM, Lonza Biosciences, Walkersville, MD). The
cells were separated, plated in T-175 flasks at 5,000 cells/cm2 and cultured in MSCGM at 37 °C
and 5% CO2. For the next two days the monolayers were washed with Dulbecco’s phosphate
buffered saline (DPBS) (Invitrogen) and fed with MSCGM every 24 hours. Thereafter media were
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changed every 48 hours and cells were cultured to confluence. First passaged cells were used for
studies.
Human ASCs (hASCs) were obtained from Lonza. The hASCs were cultured in MSCGM
(Lonza) and passaged as needed until enough cells were obtained for microencapsulation.
For the localization study, ASCs were isolated from green fluorescent protein (GFP)
positive rats (Rat Resource and Research Center, Columbia, MO) under IACUC approval at the
Virginia Commonwealth University and cultured up to passage one.
3.2.2 Alginate Microbead Production
To investigate the effect of osmolyte on alginate microbead formation, sodium chloride
(Sigma Aldrich), mannitol (Sigma Aldrich), glucose (Sigma Aldrich), and trehalose (Sigma
Aldrich) were used in the calcium crosslinking solution. Medical grade alginate (50% mannuronate
units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC BioPolymer, Sandvika,
Norway) was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX at a concentration of
20 mg/ml, resulting in a 2% alginate solution. Microbeads were created using a Nisco Encapsulator
VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle
with an inner diameter of 0.12 mm, an electrostatic potential of 6 kV and a crosslinking solution
containing 50 mM CaCl2, 150 mM osmolyte (sodium chloride, mannitol, glucose, or trehalose)
with 15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES buffer) at pH 7.3 [23,
32]. Alginate microbeads were allowed to crosslink for an additional 10 minutes, washed with
0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, and suspended in the culture media.
3.2.2.1 Degradable Alginate Microbead Production
Alginate lyase was incorporated into alginate microbeads by combining equal volumes of
4% medical grade LVM alginate and a 0.9% (w/v) saline containing 0.44 U alginate lyase/ml.
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Prior to the combination, both components were kept at 4°C. The final 2% (w/v) alginate was
mixed at 1000 rpm for one minute to produce 0.22 U alginate lyase/g alginate. The
alginate/alginate lyase mixture was used to form microbeads using a crosslinking solution
containing 75 mM CaCl2, 90 mM glucose and 10 mM HEPES using the same flow rate, nozzle
and electrostatic potential described above.
3.2.3 Effect of Osmolytes
ASCs were encapsulated in UV-sterilized medical grade alginate at a concentration of 10
x 106 cells/ml and crosslinked in a calcium solution containing one of the four osmolytes. MG63
osteoblast-like cells (American Type Culture Collection, Rockville, MD) were used as a control
population for comparison.
3.2.3.1 Alginate Microbead Morphometrics
Immediately after microbead production, images were made of microbeads suspended in
crosslinking solution. A second set of images was made once the microbeads were transferred to
the culture media (MSCGM for microencapsulated rASCs and DMEM supplemented with 10%
fetal bovine serum for microencapsulated MG63s) for at least 24 hours. The diameter of the
microbeads was analyzed with Image-Pro Plus software (version 4.5.1.22, Media Cybernetics).
Three images per well were taken using a Leica DMIL microscope connected to a Leica DC 300
camera (Leica, Solms, Germany).
3.2.3.2 LIVE/DEAD Assay
Viability of microencapsulated rASCs was measured using a LIVE/DEAD Viability kit
(Invitrogen). Samples (200 µl) were collected at weeks 1 and 2. Aliquots were transferred to a
chamber slide and incubated for 30 minutes at 37°C in 0.9% (w/v) saline containing 4 μM ethidium
homodimer-1 and 2 μM calcein-AM. Images were obtained using a Zeiss LSM 700-405 confocal
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microscope (Carl Zeiss MicroImaging, Inc., Thornwood, NY). Three images were obtained for
each well and then red and green cells were counted using Image-Pro Plus software.
3.2.3.3 Soluble Factor Quantification
To investigate the effects of osmolytes on factor production, microencapsulated hASCs
(Lonza) were cultured for 3 days in MSCGM (GM) and then treated with chondrogenic
differentiation media (CM) for 7 days. The CM consisted of high glucose DMEM (4.5 g/L glucose)
with 110 mg/L sodium pyruvate (Sigma), 50 µg/mL ascorbic acid 2-phosphate (Sigma Aldrich),
10 nM dexamethasone (Sigma Aldrich), 1% ITS+ (Sigma Aldrich), 40 µg/mL proline (Sigma
Aldrich), 100 ng/mL of the recombinant human bone morphogenetic protein 6 (BMP6, Rocky Hill,
NJ), and 10 ng/mL recombinant human transforming growth factor beta-1 (TGFβ1, R&D Systems,
Minneapolis, MN). Enzyme-linked immunosorbent assays (ELISA) were used to measure the
levels of insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), TGFβ2,
and TGFβ3 (R&D Systems) in the conditioned media and retained in the microbeads. To measure
growth factor retention within microbeads, beads were collected, uncrosslinked in 82.5 mM
sodium citrate, lyophilized, resuspended and digested in alginate lyase (1 U/ml) (Sigma Aldrich)
for an hour and assayed using ELISAs [37]. All data were normalized by the DNA content of the
cells.
3.2.3.4 DNA Quantification
Cells collected from the digested microbeads were used to determine DNA content of the
microencapsulated cells (Quant-iT™ Picogreen® ds DNA Reagent, Invitrogen).
3.2.4 Cells/Microbead and Microbeads per Unit Volume
3.2.4.1 Microbeads per Unit Volume
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To investigate the effect of the number of microbeads per unit volume, microencapsulated
hASCs (10 x 106 cells/ml alginate) were suspended in CM resulting in densities of 60,000, 12,000,
6,000, and 1,200 microbeads per well. A control group of 12,000 microbeads per well was
suspended in GM. CM or GM was added to each well, resulting in a total volume of 2 ml. On day
7 of culture, fresh media were added to each culture. Conditioned media were collected 24 hours
later and growth factor content determined by ELISA. The microbeads were collected and any
retained growth factor determined as well. Data were normalized to DNA content. Total growth
factor levels were calculated by not normalizing by the DNA content.

Cell viability was

determined as described above.
3.2.4.2 Cells per Microbead
To investigate the effect of cell number per bead, hASC suspensions (20, 10, 5 and 2 x 106
cells/ml alginate) were microencapsulated to produce microbeads containing 71, 37, 21, and 7 cells
respectively. Microbeads were cultured in CM. A control group (37 cells per microbead) was
cultured in GM. Growth factor production was determined as described above. Cell viability was
determined.
3.2.4.3 Cell Release
To determine if alginate lyase mediated degradation was altered by the number of cells per
bead or the number of beads per well, hASCs were encapsulated in microbeads containing 0 or
0.06 units of enzyme per g of UV-sterilized medical grade alginate. The microbeads were
suspended in 40 µm cell strainers (BD Falcon, Franklin Lakes, NJ) and cultured in CM in nontissue culture treated 6-well plates to limit proliferation of released cells in the well. Media were
changed every 48 hours and each cell strainer was washed twice with 0.9% (w/v) saline to ensure
that all the cells released were collected. Any additional cells on the plate’s surface were collected
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by trypsinization. For the groups where alginate microbeads did not fully degrade by the end of
the 12 day period, 82.5 mM sodium citrate was used to release the remaining cells. DNA was
quantified as described previously. Alginate microbead degradation was monitored using light
microscopy. At each time point one image per group was taken.
3.2.5 Retention of Cells In Vivo
3.2.5.1 Cell Labeling
GFP-rASCs were labelled with DiR (1,1’-dioctadecyltetramethyl indotricarbocyanine
iodide) fluorescent dye (PerkinElmer, Waltham, MA) to more effectively distinguish their
fluorescence (Absorption\Emission: 748/780 nm) from the autofluorescence of the surrounding
tissue which also fluoresces green [38]. The optimal dye concentration for labeling GFP-rASCs
while maintaining viability was previously determined over a two week period with dye
concentrations ranging from 4.2 µg/ml to 135 µg/ml. A million cells were incubated in the
respective dye concentration for 30 minutes at 37°C. After labeling was complete, cells were
washed with PBS twice. Immediately after staining with DiR, a portion of the cells were used for
viability measurements. The viability was quantified with a cell counter (Countess, Invitrogen)
and trypan blue (Lonza). The remaining cells were then plated at 5000 cells/cm2 in 24-well plates
and 96-well black with a clear bottom for viability and fluorescence measurements on days 7 and
14. At each time point, DiR fluorescence was quantified using Odyssey Infrared Imaging System
(Li-Cor, Lincoln, NE) while the GFP fluorescence was quantified using a plate Synergy H1 reader
(BioTek, Winooski, VT).
3.2.5.2 Microbead Injection Protocol
Microencapsulated GFP-rASCs were delivered intramuscularly to athymic nude mice
under a protocol approved by the IACUC at Virginia Commonwealth University. GFP-rASCs
were labelled using 33.8 µg/ml DiR dye and then microencapsulated in microbeads containing 0
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U, 0.06 U, 0.22 U and 1.75 U per g medical grade alginate microbeads. Microbeads were
suspended in 1 ml saline and 100 µl were injected into the right gastrocnemius and left deltoid of
each mouse using a 27 gauge needle. An equivalent number of cells in a suspension were injected
as a control. (n=4, per variable)
3.2.5.3 Analysis of Results
Retention of microencapsulated cells at the injection site was followed with a Maestro 2
Imaging System (PerkinElmer, Waltham, MA) [38]. Images were taken on days 0 (immediately
after the injection), 1, 2, 4, 6, 8, 10, 12 and 14. Animals were placed in a prone or either lateral
recumbent positions on the imaging platform while under anesthesia (2% isoflurane in oxygen).
On the final day, animals were euthanized and an ex vivo organ assessment conducted to identify
the presence of labeled GFP-rASCs. Inguinal lymph nodes, sternum, heart, lung, liver, spleen,
stomach, intestines, both kidneys, and testes were removed and imaged. Fluorescence was
quantified and normalized to the fluorescence measured on day 0 for each animal’s arm or thigh.
Images were converted to a scaled image by applying a threshold of 0.01 scaled counts/second. To
quantify the fluorescence, an area of interest was selected and the threshold applied using Maestro
2.10 software (PerkinElmer, Waltham, MA). The viability of the same batch of cells delivered to
the animals was measured in vitro at each imaging time point using the Cell Titer-Glo Luminescent
Cell Viability Assay (Promega, Madison, WI).
3.2.6 Inflammation
In vivo studies were performed to determine if the degradation by-products generated by
alginate lyase elicit a delayed hypersensitivity inflammatory response. Male C57 Black 6 mice
were handled under a protocol approved by the IACUC at Virginia Commonwealth University.
Prior to surgeries, mice were anesthetized using isoflurane gas. Non-degradable (0 U/g) and
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degradable (0.22 U/g) alginate microbeads (0.1 ml) without cells were injected subcutaneously on
the dorsum using a 27 gauge needle [4]. Each animal received one injection subcutaneously above
the right gastrocnemius (n = 6 for each experimental condition). After 2 weeks each animal
received another injection above the left gastrocnemius. Animals were euthanized by CO2
inhalation after 6 weeks and a portion of the leg removed and processed for histology as described
below.
After 48 hours of fixation in formalin, samples were dehydrated in a series of 95% and
100% ethanol and xylene washes. Samples were embedded in paraffin, and cut into 7-μm thick
sections (Shandon Finesse 325, Thermo Scientific). The sections were stained with haematoxylin
and eosin, and then imaged with a Leica DMLB microscope (Leica Microsystems, Bannockburn,
IL). Images were analyzed for the presence of inflammatory cells.
3.2.7 Statistical Analysis
The results of the in vitro assays were calculated as the means ± SEM of six independent
cultures per variable. The results from the in vivo study examining retention of cells were
calculated as the means ± SEM of 4 animals per variable. Statistically significant differences
between groups were determined by one-way ANOVA followed by Bonferroni’s modification of
Student’s t-test. P values ≤ 0.05 were considered significant. All experiments were repeated at
least twice to ensure validity of results, with the exception of the in vivo studies. Data presented
are from representative experiments.

37

3.3. Results
3.3.1 Effect of Osmolytes
3.3.1.1 Microbead Diameter
Microbeads had a spherical morphology that was unchanged by osmolyte type or presence
of cells (Fig. 3.1A). Inclusion of cells increased microbead diameters by 30% regardless of
osmolyte. All microbead formulations exhibited an increase in diameter when transferred from the
crosslinking solution to culture medium, whether or not cells were present. Alginate microbeads
without cells had the largest increase in diameter upon transfer to culture media (Fig. 3.1B). A
smaller increase was observed in alginate microbeads incorporating rASCs or MG63 cells (Fig.
3.1C-D). Microbeads fabricated with glucose as the osmolyte had the smallest diameter.
Furthermore, glucose maintained diameters below 200 µm in microbeads transferred to culture
media.
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Figure 3.1: The diameter of alginate microbeads crosslinked in calcium chloride solutions made
with different osmolytes. (A) Alginate microbeads incorporating no cells suspended in the
crosslinking solution and full media, and incorporating rASCs suspended in MSCGM under an
inverted light microscope (mag. = 10x). (B) Microbeads incorporating no cells. (C) Microbeads
incorporating rASCs. (D) Microbeads incorporating MG63s. Data were analyzed using one-way
ANOVA followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. calcium
chloride, $ vs. sodium chloride, # vs. mannitol, + vs. glucose.
3.3.1.2 Effects of Osmolytes on ASC Viability
The type of osmolyte did not impact cell viability (Fig. 3.2A). No differences were noted
in the ratio of live to dead cells amongst microbead types, nor was there a difference between 7
and 14 days in culture (Fig. 3.2B).
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Figure 3.2: Viability of microencapsulated rASCs crosslinked in calcium chloride solutions made
with different osmolytes (Scale bar = 50 µm). (A) LIVE/DEAD staining of released ASCs, where
green represents live cells and red represents dead cells and (B) the percent viable cells. Data were
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p <
0.05 vs. sodium chloride, # vs. mannitol, a vs. day 7.
3.3.1.3 Growth Factor Production
The osmolyte did not impact production of TGFβ2, TGFβ3, IGF-1 and VEGF, either
secreted into the culture media or retained with the microbeads after treatment with CM for 7 days
(Table 3.1).
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Table 3.1. Growth factor secreted in media and retained in the microbeads by microencapsulated
cells treated with chondrogenic media.

Growth Factor in Media/DNA (ng/µg)
VEGF
NaCl 15 ± 1.6
Mannitol 12 ± 0.7
Trehalose 14 ± 1.8
Glucose 12 ± 0.8

IGF-1
8 ± 0.5
7 ± 0.5
7 ± 0.6
7 ± 0.4

TGF-β2
15 ± 0.8
14 ± 1.0
12 ± 1.2
13 ± 0.8

TGF-β3
14 ± 0.8
13 ± 1.0
12 + 0.6
11 ± 1.1

Growth Factor Retained in Microbeads/DNA
(ng/µg)
VEGF
IGF-1
TGF-β2 TGF-β3
12 ± 0.9 18.0 ± 1.0
33 ± 2.1 30 ± 1.7
16 ± 3.0
16.9 ±1.2
29 ± 1.8 28 ± 1.9
13 ± 1.5 15.0 ± 1.4
28 ± 2.3 26 ± 1.6
13 ± 0.8 15.8 ± 1.0
28 ± 1.9 25 ± 2.2

3.3.2 Number of Microbeads per Volume
Growth factor production was sensitive to microbead number per unit volume. As the
number of microbeads increased per well, IGF-1, VEGF, TGFβ2 and TGFβ3 production per cell
decreased both inside the microbead and in the surrounding media (Fig. 3.3). Compared to beads
cultured in MSCGM, microbeads cultured in CM produced and retained reduced levels of VEGF.
The total amount of growth factor produced per well was relatively insensitive to the
number of microbeads per unit volume (Fig. 3.3). Compared to microbeads cultured in GM,
microbeads cultured in CM produced slightly more IGF-1, but this was only statistically higher in
wells with the lowest number of microbeads (Fig. 3.3E). Total VEGF levels in the microbeads
and in the conditioned media was elevated when microbeads were cultured at the highest density
(Fig. 3.3F). In contrast, the amounts of TGFβ2 and TGFβ3 were comparable at all microbead
densities.
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Figure 3.3: Effect of microbead density per unit volume on growth factor production by
microencapsulated hASCs. Microbeads were cultured for 7 days in MSCGM or CM, Top row protein levels normalized by DNA: (A) insulin growth factor 1 (IGF-1), (B) vascular endothelial
growth factor (VEGF), (C) transforming growth factor beta 2 (TGFβ2), and (D) transforming
growth factor beta 3 (TGFβ3) in conditioned media and retained in the microbead, Bottom row –
total IGF-1 (E), VEGF (F), TGFβ2 (G), and TGFβ3 (H) in conditioned media and retained in the
microbead,. Data were analyzed using one-way ANOVA followed by Bonferroni’s modification
of Student’s t-test. * p < 0.05 vs. 12 GM, # vs. 60 CM, $ vs. 12 CM, and ^ vs. 6 CM.
3.3.3 Cells per Microbead
Alginate microbeads encapsulating the smallest number of cells produced the highest IGF1, VEGF, TGFβ2 and TGFβ3 level per cell (Fig. 3.4). Control microbeads, which contained 37
cells per bead, produced similar levels of IGF-1, VEGF, TGFβ2 and TGFβ3 in MSCGM as
microbeads cultured in CM. However, CM suppressed VEGF secreted into the medium although
there were no differences in VEGF retention in the microbead.
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The total amount of growth factor produced per well was relatively insensitive to the
number of cells per microbead (Fig. 3.4). Compared to microbeads cultured in GM, cells cultured
in CM retained more IGF-1 in the microbead, but the number of cells per microbead did not impact
this result, nor was there an effect on the number of cells on the amount of IGF-1 in the media
(Fig. 3.4E). Total VEGF levels in the microbeads and in the media were reduced in CM cultures
(Fig. 3.4F). Only in microbeads containing 37 cells was there a statistically relevant increase in
VEGF compared to other cell densities and this was only evident in the microbead. Cell number
per bead had only minor effects on TGFβ2 and TGFβ3.

Figure 3.4: Effect of cell number per microbead on growth factor production by microencapsulated
hASCs. Protein levels normalized by DNA: (A) insulin growth factor 1 (IGF-1), (B) vascular
endothelial growth factor (VEGF), (C) transforming growth factor beta 2 (TGFβ2), and (D)
transforming growth factor beta 3 (TGFβ3) in conditioned media and retained in the microbead,
Total protein levels of IGF-1 (E), VEGF (F), TGFβ2 (G), and TGFβ3 (H) in conditioned media
and retained in the microbead,. Data were analyzed using one-way ANOVA followed by
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Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. 37 GM, # vs. 71 CM, $ vs. 37 CM,
and ^ vs. 21 CM.
3.3.4 Effect of Alginate lyase
Release of cells from the microbeads varied with the number of microbeads per well (Fig.
3.5A). At the highest number of microbeads cell release was delayed compared to the other groups.
These microbeads released 59% of their cells on day 12. The number of cells per microbeads did
not affect the rate of cell release (Fig. 3.5B).

Figure 3.5: (A) The effect of microbead density per well on cell release from microbeads
containing 0.06 U/g alginate lyase/alginate over a 12 day period. (B) The effect of number of cells
per microbead on cell release from microbeads containing 0.06 U/g alginate lyase/alginate.
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Percent DNA of all cells released. Data were analyzed using one-way ANOVA followed by
Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 2.
3.3.5 Cell Viability
Cell viability was greatest when microbeads were cultured in GM compared to CM (Table
3.2). However, there were no differences in viability as a function of the number of microbeads
per unit volume amongst the cultures grown in CM. Similarly, cells grown in CM had reduced
viability compared to GM, but no differences in cell viability as a function of cells per microbead
were noted when microbeads were cultured in CM.

Table 3.2: Effects of microbead number per well and number of cells per microbead on cell
viability. Microbead were cultures for 7 days in MSCGM (GM) or chondrogenic medium (CM),
* p < 0.05 vs. GM.
Media
Microbeads x 103/well
% Viability
Cells/Microbead
% Viability

GM
12
99 ± 0.2
37
98 ± 0.4

CM
60
89 ± 2.4
71
91 ± 1.6*

CM
12
91 ± 1.4
37
90 ± 0.8*

CM
6
87 ± 1.8*
21
93 ± 0.7

CM
1.2
82 ± 5.2*
7
91 ± 2.9*

3.3.6 Degradable Microbeads and Cell Retention
Degradable microbeads were able to retain cells at the treatment site for the 14 day test
period (Fig. 3.6). In contrast, sites treated with cell suspensions showed decreased fluorescence as
early as day 1. Gastrocnemius muscle injected with microbeads containing 1.75 U enzyme/g
alginate exhibited decreased fluorescence at day 8 whereas reduced fluorescence as observed in
the deltoid by day 4.
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Only the inguinal lymph node had a detectable fluorescence signal. The right inguinal
lymph nodes for animals receiving the cell suspension had a significantly higher fluorescence
compared to the left inguinal lymph node and right inguinal lymph nodes of animals in the other
treatment groups (Fig. 3.7).

46

Figure 3.6: In Vivo localization of rASCs. (A) Fluorescent images indicating the location of
delivered cells and (B) percent change in the fluorescence from day 0 in the right gastrocnemius,
(C) fluorescent images indicating the location of delivered cells and (D) percent change in the
fluorescence from day 0 in the left deltoid of animals receiving a cell suspension (CS),
microencapsulated cells in 0 U/g, 0.06 U/g, 0.22 U/g, and 1.75 U/g microbeads on days 1, 2, 4, 6,
8, 10, 12 and 14. Data were analyzed using one-way ANOVA followed by Bonferroni’s
modification of Student’s t-test. * p < 0.05 vs. day 1 and # vs. day 2.

Figure 3.7: Ex vivo organ assessment (A) Fluorescent images of the inguinal lymph nodes, heart,
sternum, and lung (B) quantification of the fluorescent signal from both right and left inguinal
lymph nodes of animals receiving a cell suspension (CS), microencapsulated cells in 0 U/g, 0.06
U/g, 0.22 U/g, and 1.75 U/g microbeads in the right gastrocnemius and left deltoid on day 14. Data
were analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test.
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* p < 0.05 vs. right inguinal lymph node and # vs. the respective inguinal lymph node in the cell
suspension group.
3.3.7 Inflammatory Response to Degradable Alginate Microbeads
Non-degradable microbeads were still present at 6 weeks and histological sections showed
no infiltration of white blood cells (Fig. 8A). Degradable microbeads were not present in tissue
sections at the end of the experiment and two of the 5 animals had an infiltration of foamy
histiocytes. One animal from each group died during the length of the experiment. However, the
cause of death was not linked to alginate microbeads or alginate lyase delivered.

Figure 3.8: H&E staining of subcutaneous site of alginate microbead implantation after 6 weeks:
(A) alginate microbeads (0 U/g), scale bar represents 500 µm; (B) scale bar represents 100 µm,
arrows indicate alginate microbeads; (C) alginate microbeads incorporating alginate-lyase (0.22
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U/g), scale bar represents 200 µm, the arrow head indicates the implantation site; and (D) alginate
microbeads incorporating alginate lyase (0.22 U/g), scale bar represents 20 µm.

3.4. Discussion
The results of this study confirm that injectable microbeads containing ASCs generated
using an electrostatic potential will remain viable in vitro and in vivo. They also show that organic
and inorganic osmolytes can be used as alternatives to glucose in the crosslinking solution without
negatively impacting cell viability or production of key growth factors, although there are small
changes in microbead diameter. The microbeads were transferred to culture medium 10 minutes
after being exposed to the cross-linking solution so any positive effects of using a nutrient osmolyte
like glucose versus non-nutrient osmolytes like trehalose, mannitol or NaCl was not addressed in
this study.
The diameter of the alginate microbeads affects injectability and the mass transfer of
nutrients to the encapsulated cells. The smallest diameters were observed when using glucose, but
in all cases diameters were 200 µm or less prior to transfer into culture media. Whether cells were
present or not, the microbeads increased in diameter once they were transferred from calcium
crosslinking solution to the respective media. This may have resulted from a change in pH. It is
known that once anionic polymers like alginate are placed in media with a pH higher than the pKa
of the polymer’s ionic groups, the swelling ratio increases [39]. A change in the water gradient,
produced by a low water concentration in the crosslinking solution (75 mM CaCl 2) and a higher
water concentration in the media (1.8 mM Ca2+), may also play a role. In addition, alginate
hydrogels have been known to swell once they are placed in tissue culture media due to the
presence of chelators, monovalent ions, and non-crosslinking divalent cations like Mg++, resulting
in an increase in alginate porosity [40, 41]. Viability of cells in vivo is important to the regenerative
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success of any cell-based therapy because it affects the ability of the cells to aid in tissue
regeneration. The viability of rASCs microencapsulated in all four types of crosslinking solutions
had a relatively high viability and this was at 80% across all groups even at two weeks. This
confirms our previous observations and suggests that as long as the microencapsulated cells are in
a nutrient rich environment, the nature of the osmolyte is not a critical factor. Further support for
this is the fact that the osmolyte did not change the ability of the cells to produce growth factors.
As a result using any of the osmolytes should be equally acceptable for hASCs. However this may
change if other cell types are used.
Our findings indicate that growth factor production is more sensitive to the culture medium
than to either the number of microbeads per unit volume or the number of cells per microbead.
The results showed that where the smallest number of microbeads were present there was the
largest amount of growth factor per cell being produced. This is not surprising as the supply of
nutrients is greater when cells are competing for a finite resource. Similarly fewer cells per
microbead correlated with greater production of growth factors. This suggests that a therapeutic
result may be more effectively achieved using few beads containing fewer cells per bead.
Assuming diffusivity to be constant, growth factors secretion into the medium would be sensitive
to the medium, as was the case when microencapsulated rASCs were cultured in CM versus
MSCGM.
Unlike growth factor production, alginate-lyase mediated cell release was affected by the
number of microbeads. As the microbead density increased, the rate of degradation decreased.
Microbead degradation involves two mechanisms. At early time points, the enzyme’s activity is
more prominent, leading to cleavage of the glycosidic bonds. At later time points, however, the
stability of the alginate decreases due to an influx of monovalent ions from the surrounding media
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and subsequent ion exchange with Ca++. Thus at lower microbead concentrations, there is a greater
amount of monovalent ions present in each well to displace Ca++ and hence, an earlier release of
cells [34]. The number of cells per microbead was only important in so for as the cells reduced the
volume of alginate. Only at the lowest number of cells per microbead, was cell release negligible
and this may reflect an inability to detect the released cells as much as it reflects the greater alginate
content.
The microbeads successfully retain cells at the treatment sites in contrast to cells injected
as a suspension. As we reported previously [34], microbeads containing 1.75 U alginate lyase per
gram alginate degraded the most rapidly, and released cells from these microbeads migrated from
the treatment sites by day 4 in the deltoid muscle and by day 8 from the gastrocnemius. Loss of
cells from the muscles may have been affected by differences in vasculature or differences in
loading [42]. In both cases however, even in the fast degrading microbeads, cells were effectively
retained for up to a week. These results also show that cell retention can be achieved in a controlled
manner by varying the enzyme content of the microbeads.
One concern is that the imaging method used in this study is detecting artifact remaining
following cell death, as has been observed in studies using fluorescent nanoparticles to label cells
[43]. It is unlikely that the GFP-labelled ASCs became distributed to other tissues, however. In the
treatment groups where migration was observed, the lymph nodes were the only organs positive
for the DiR dye used to stain the cells. A significantly higher fluorescence was present in the right
inguinal lymph node, showing that cells may have migrated to that organ since the microbeads
were delivered in close proximity to the right lymph node. The lymph nodes belonging to animals
receiving the cell suspension had the highest fluorescence. Although the other groups had
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detectable fluorescence additional studies must be done to confirm the presence of DiR labelled
GFP cells at the treatment site.
Alginate is a biocompatible hydrogel; however, the biocompatibility of alginate lyase or
the byproducts of alginate lyase mediated degradation is not known. Our previous results indicate
that after a single exposure, no inflammation is present, even when alginate-lyase is included [34].
Here, we examined whether a delayed hypersensitivity reaction was possible. At 6 weeks after a
second injection, alginate microbeads were still present whereas alginate microbeads incorporating
alginate lyase were no longer detectable. Histological sections from animals receiving nondegradable alginate microbeads had no evidence of macrophages while 2 animals receiving
degradable alginate microbeads had an infiltration of foamy histiocytes (macrophages with
abundant cytoplasm), indicating the presence of inflammation. It is possible that the byproducts of
alginate-lyase mediated degradation may have elicited an inflammatory response earlier in the time
line of the study that was resolved. This illustrates that the byproducts of alginate lyase mediated
degradation may elicit a mild chronic inflammatory response but comparatively less than the
response elicited by sutures [44]. These results are inconclusive with respect to a delayed
hypersensitivity reaction.

3.5. Conclusions
This study investigated a number of variables associated with the clinical use of alginate
microbeads for tissue regeneration applications. Glucose was found to be the optimal osmolyte as
it relates to the smallest alginate microbead diameter. Both microencapsulated cell viability and
growth factor production were found to be osmolyte-independent. Only a small number of alginate
microbeads and a low cell density may be required to achieve the same levels of growth factor
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production as delivering a high number of alginate microbeads with a higher cell density. The rate
of cell release can be modulated by the number of microbeads, the number of cells per microbead
and the concentration of alginate lyase. Clinically, a low microbead density and a low microbead
cell density can be used to achieve similar growth factor production as higher density groups;
however the time of cell release may be delayed. Degradable alginate microbeads can be used to
localize microencapsulated cells at the delivered site. However, alginate microbeads incorporating
alginate lyase may elicit a mild chronic inflammatory response upon repeated exposures.

53

CHAPTER 4

The Production of Osteogenic and Angiogenic Factors from of
Microencapsulated ASCs is Species Dependent and can be Modified by the
Pretreatment of Media used.

Summary
Cell-based therapies can provide additional cells at an injury site to aid in regeneration
especially when a large amount of tissue is removed or the host’s stem cells are compromised by
disease or age. However, present modes of delivering stem cells lead to low viability and cell
dispersal, limiting the contribution of the cells to the repair process. We previously showed that
adipose stem cells (ASCs) can be localized in tissues by encapsulating them in injectable alginate
microbeads generated using an electrostatic potential and Ca++ crosslinking solution containing an
organic osmolyte. The microencapsulated cells constitutively produce angiogenic factors but
when treated with chondrogenic medium, support chondrogenesis in vivo. Here, we investigated
the effects of osteogenic medium (OM) on encapsulated rat ASCs (rASCs) and determined the
optimal combination of OM components that will lead to the production of both osteogenic and
angiogenic factors. Our results showed that microencapsulated rASCs cultured in growth medium
(GM) produced angiogenic (VEGF, FGF2) and osteogenic (BMP2) factors. OM, which contains
dexamethasone (d) and ascorbic acid (aa), reduced VEGF in cultures of rASCs, mouse ASCs
(mASCs) and human ASCs (hASCs), but not in cultures of rabbit ASCs (rbASCs). OM without
dexamethasone (OM-d), but not OM without ascorbic acid (OM-aa), restored angiogenic factor
production by rASCs to levels observed in GM. Unlike rASCs, BMP2 levels secreted by rbASCs,
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mASCs, and hASCs were not affected by treatment media. In conclusion, microencapsulated
ASCs can be treated to produce osteogenic and angiogenic factors to aid in the bone repair process,
but the effects of the media are species specific.
4.1 Introduction
Paracrine signaling from multipotent mesenchymal stem cells (MSCs) has a therapeutic
effect on wound repair.

These cells are involved in the three phases of wound repair –

inflammation, proliferation, and remodeling, by producing proteins that influence cell migration,
proliferation, angiogenesis, and survival of surrounding cells [45]. In bone regeneration, MSCs
contribute by producing osteogenic factors, like bone morphogenetic protein-2 (BMP2) and
angiogenic factors like fibroblast growth factor-2 (FGF2) and vascular endothelial growth factor
(VEGF), in addition to modulating inflammation [46].
Given the important role MSCs play in the bone repair process, augmenting sites
of wound repair and fractures at risk for forming non-unions with MSCs would be advantageous,
especially in cases where the stem cell population is insufficient or otherwise compromised by
disease, immunodeficiency, smoking and age. However, to harness the full potential of these
therapies, the cells must be viable and maintain their phenotype after delivery. Unfortunately,
delivery as an injectable suspension or on an implantable scaffold often leads to low cell viability,
limiting the therapeutic effect of the cells.
We developed an injectable microbead technology using alginate hydrogels to encapsulate
cells within 200 µm diameter spheres, thereby protecting the cells from shear during injection and
providing a high mass to volume ratio, enhancing their mass transfer properties [23, 47]. Alginate
is a co-block polymer that consists of pure mannuronic acid (M) blocks and pure guluronic acid
(G) blocks, or alternating MG blocks [24]. The hydrogel is formed when M units form an ionic
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bond with a divalent cation.

In our system, an alginate-cell suspension is exposed to an

electrostatic potential of 6kV to generate the microbeads, followed by cross-linking the alginate in
a Ca++ solution containing glucose as an osmolyte. The number of cells per microbead is tunable
and depends on the number of cells in the original suspension. Using this technology, we have
shown that the encapsulated cells remain viable in cell culture for at least 3 weeks and in vivo for
at least 3 months [5]. Moreover, encapsulated adipose stem cells (ASCs) are able to produce
factors that stimulate angiogenesis in vitro and in vivo, and when pretreated with chondrogenic
medium, produce factors that support chondrogenesis [37, 48].
The goal of the present study was to determine if the microbead technology could be
adapted for use in bone regeneration strategies. ASCs are multipotent and have the ability to
differentiate into osteoblasts when treated with BMP2 or when cultured in osteogenic medium
(OM) containing dexamethasone , ascorbic acid 2-phosphate, and beta-glycerol phosphate [2, 36].
It is not known if microencapsulated ASCs differentiate into osteoblasts when cultured in OM or
if OM affects production of either osteogenic or angiogenic factors. We previously showed that
growth factor production by monolayer cultures of ASCs was sensitive to treatment with
dexamethasone and ascorbic acid 2-phosphate, two of the components of OM [37].
Dexamethasone decreased VEGF; ascorbic acid 2-phosphate increased FGF2. However, when the
ASCs were cultured in chondrogenic medium, removal of dexamethasone resulted in an increase
in VEGF and removal of ascorbic acid 2-phosphate resulted in a decrease in FGF2. These
observations led us to hypothesize that treatment with OM would support osteogenic
differentiation of microencapsulated ASCs and stimulate production of factors associated with
osteogenesis, including BMP2 and VEGF. Moreover, production of these factors could be tuned
by manipulating the dexamethasone and ascorbic acid 2-phosphate content of the OM.
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4.2 Methods
4.2.1 Adipose Derived Stem Cells
ASCs were isolated from the inguinal fat pads of 100-125g male Sprague-Dawley rats,
male New Zealand White rabbits, and C57 Black 6 (C57Bl/6) mice under Institutional Animal
Care and Use Committee (IACUC) approved protocols at the Georgia Institute of Technology and
Virginia Commonwealth University as described previously [2, 36].
The cells were separated, plated in T-175 flasks at 5,000 cells/cm2 and cultured on tissue
culture polystyrene (TCPS) in mesenchymal stem cell growth medium (GM, Lonza, Walkersville,
MD) at 37°C and 5% CO2. For the next two days the monolayers were washed with Dulbecco’s
phosphate buffered saline (DPBS) (Invitrogen) and fed with GM every 24 hours. Thereafter media
were changed every 48 hours and cells were cultured to confluence. First passage cells were used
for all studies.
Human ASCs from three different donors were obtained from Lonza, and cultured to a passage
where enough cells were present for each study.4.2.2 Microencapsulated Cells
To form microbeads, ASCs were encapsulated in UV-sterilized medical grade alginate
(50% mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC
BioPolymer) at a concentration of 107 cells/ml. Medical grade alginate was dissolved in 0.9%
(w/v) saline (Ricca Chemical, Arlington, TX) at a concentration of 40 mg/ml. Microbeads
incorporating cells were created using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco
Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle with an inner diameter of 0.12
mm, and an electrostatic potential of 6 kV. The crosslinking solution contained 50 mM CaCl2, 150
mM glucose with 15 mM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] (Sigma
Aldrich) at pH 7.3 (Sigma Aldrich) [5, 23]. Alginate microbeads were allowed to crosslink for an
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additional 10 minutes, washed with 0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++,
and suspended in the respective culture medium.
4.2.3 Effect of Microencapsulation on Growth Factor Production
To investigate the effect of microencapsulation on the ability of ASCs to produce
angiogenic and osteogenic factors, microencapsulated ASCs derived from Sprague Dawley rats
(rASCs) were compared to monolayer cultures of rASCs grown on TCPS. Microbeads containing
rASCs were cultured for five days in GM. At that time, one half of the cultures were maintained
in GM and the other half switched to OM for an additional five days. rASCs were plated at 5000
cells/cm2 and grown five days in GM, followed by five days in OM. In addition, rat osteoblasts
(ROBs) were plated at 5000 cells/cm2 and were grown for all 10 days in Dulbecco’s modified
Eagle medium containing 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA) as a positive
control.
4.2.4 Effects of Dexamethasone and Ascorbic acid 2-phosphate
To investigate the contributions of dexamethasone and ascorbic acid 2-phosphate to the
response of microencapsulated ASCs to OM, microbeads incorporating rASCs (37
cells/microbead) were cultured in GM for 5 days. At that time, media were changed and
microbeads were cultured for an addition 5 days in GM, OM, OM without ascorbic acid 2phosphate (OM-aa), OM without dexamethasone (OM-d), or OM without ascorbic acid 2phosphate and dexamethasone (OM-aa-d). In order to specifically address the role of
dexamethasone, rASC microbeads were cultured in GM for 5 days and an additional 5 days in
GM, GM with dexamethasone (GM+d), OM, or OM-d.

To examine whether effects of

dexamethasone on growth factor production by microencapsulated ASCs is species specific,
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microbeads containing ASCs derived from mice, rats, rabbits and humans (37 cells/microbead)
were cultured in GM for 5 days and an additional 5 days in GM, OM, and OM-d.
4.2.5 Soluble Factor Quantification
Enzyme-linked immunosorbent assays (ELISAs) were used to measure the levels of
vascular endothelial growth factor A (VEGF), fibroblast growth factor 2 (FGF2), and bone
morphogenetic protein 2 (BMP2) (R&D Systems, Minneapolis, MN) in the conditioned media of
monolayer cultures and microbead cultures. We also assayed any growth factors retained within
the microbeads. To do this, beads were collected, uncrosslinked in 82.5 mM sodium citrate,
lyophilized, resuspended, digested in alginate lyase (1 U/ml) (Sigma Aldrich) for one hour and
assayed.[37]
All ELISAs were normalized by the DNA content of the cells. Cells layers were lysed in
0.05% Triton-X100 (Sigma Aldrich). Cells were collected from the digested microbeads by
centrifugation and lysed in Triton-X100. DNA content of the lysates was determined using the
Quant-iT™ Picogreen® ds DNA Reagent (Invitrogen) according to the manufacturer’s directions.
4.2.6 RNA Extraction and Real Time PCR
For these analyses, cells were collected by centrifugation from the digested beads and RNA
was extracted by adding TRizol ® [Invitrogen] to the resulting cell pellet, which was homogenized
using a Qiashredder (QIAGEN, Valencia, CA). RNA was extracted using chloroform and
isopropanol (Sigma Aldrich), and quantified with the Nanodrop Spectrophotometer (Thermo
Scientific, Waltham, MA). Samples were then converted into cDNA by the reverse transcription
of 1 µg RNA with random primers (Applied Biosystems, Warrington, UK) and Multiscribe
Reverse Transcriptase (Applied Biosystems). mRNA levels were measured by real-time PCR
using the StepOne Plus PCR System (Applied Biosystems). mRNA levels for the following
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proteins were measured; BMP2 (Bmp2), FGF2 (Fgf2), transforming growth factor beta-1 (Tgfβ1)
and VEGF-A (Vegfa). In addition the mRNA levels for BMP antagonists, Noggin (Nog) and
Gremlin 1 (Grem1) were measured. All primers (Table 4.1) were designed using the Beacon
Designer 7.0 program and then synthesized by the Eurofins MWG Operon (Huntsville, AL).
mRNA levels were quantified relative to a standard curve of known concentration, and results
were normalized to the transcript levels of the housekeeping gene, 40S ribosomal protein S18
(Rps18).

Table 4.1: Primer sequences used for the analysis of mRNA levels.
Gene
Bmp2
Fgf2
Grem1
Nog
Rps18
Tgfβ1
Vegfa

Forward Primer
Reverse Primer
TGT GAG GAT TAG CAG GTC TTT G CTT CCG CTG TTT GTG TTT GG
Qiagen QuantiTect Primer 00189035
ATC AGC GAC AGA CGG GGC
AAG CAC ATC ACC GGC CAA CGG
ATC T
GCC AGC ACT ATC TAC ACA TCC
CAG CAG CGT CTC GTT CAG
TCG CTA TCA CTG CCA TTA AGG
TGT ATT GTC GTG GGT TCT GC
AGCCTGCTTCTTGAGTCC
AAGTGGGGTGTTCTTAAATAGG
GGA CAT CTT CCA GGA GTA CC
TCC AGG GCT TCA TCA TTG C

4.3 Results
rASCs cultured on TCPS and in alginate microbeads treated with OM had significantly
lower DNA content compared to groups that received GM treatment (Fig. 4.1A). The DNA content
of rat osteoblasts was significantly lower than rASCs in monolayer cultured in GM or OM.
Microencapsulated rASCs receiving treatments with GM or various combinations of OM and its
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components had similar DNA content. In some experiments, the OM-d group had lower DNA
compared to OM-aa (Fig. 4.1B) or OM (Fig. 4.1C).

Figure 4.1: A) DNA content of confluent monolayer cultures of rASCs grown in GM and OM on
tissue culture polystyrene (TCPS). DNA content of rat osteoblasts are shown for comparison.
DNA content of microencapsulated rASCs (μB) cultured in GM and OM for 5 days. (B) Effect of
removing ascorbic acid (aa) or dexamethasone (d) from OM on DNA content of microencapsulated
rASCs. Microbeads were cultured in GM, OM, OM-aa, OM-d, OM-aa-d for 5 days. (C) Effect
of dexamethasone on DNA content of microencapsulated rASCs. Microbeads were cultured in
GM, GM+d, OM, or OM-d for 5 days. Data were analyzed using one-way ANOVA followed by
Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. GM, $ vs. OM, # vs. TCPS.
Similar VEGF levels were produced by monolayer cultures and microbeads treated with
GM. Rat osteoblasts produced 3 times less VEGF compared to rASCs cultured in GM. VEGF
levels were reduced after OM treatment in both monolayer and microencapsulated cultures (Fig.
2A). A similar reduction in VEGF levels was seen after microencapsulated rASCs were treated
with OM-aa and GM+d (Figs. 4.2B, 4.2C). However, similar VEGF levels were attained as in GM
groups once microbeads were treated with either OM-d or OM-aa-d (Figs. 4.2B, 4.2C). OM treated
microencapsulated rASCs produced significantly less VEGF compared to GM for many
experiments (Fig. 4.2D). Little or no FGF2 was detected in the conditioned media from all cell
types cultured on TCPS or microencapsulated rASCs independent of the treatment (Figs. 4.2E –
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4.2H). There was at least a 100% increase in BMP2 levels produced by microencapsulated rASCs
cultured in GM or OM compared to their respective monolayer cultures (Fig. 4.2I). The BMP2
levels were equivalent for all cell types cultured on TCPS and regardless of the treatment (Fig.
4.2I). OM-aa, OM-d, and OM-aa-d treated groups secreted significantly less BMP2 compared to
the GM treated group (Fig. 4.2J). However, BMP2 levels produced by microencapsulated rASCs
treated with OM are similar compared to GM (Fig. 4.2L) despite the fluctuations observed (Figs.
4.2J, 4.2K). A treatment over control analysis for many experiments demonstrates that BMP2
levels between GM and OM are not different.

Figure 4.2: (A) VEGF in the conditioned media of monolayer cultures of rASCs and
microencapsulated ASCs cultured for 5 days in GM and OM. Monolayer cultures of rat osteoblasts
grown in their respective media for 5 days are shown for comparison. (B) Effect of removing
ascorbic acid (aa) or dexamethasone (d) from OM on factor production by microencapsulated
rASCs after 5 days in GM, OM, OM-aa, OM-d, OM-aa-d for 5 days. (C) Effect of dexamethasone
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on factor production by microencapsulated rASCs cultured in GM, GM+d, OM, or OM-d for 5
days.

(D) Effect of OM v. GM on VEGF, FGF2, and BMP2 in conditioned media of

microencapsulated rASCs. GM values are indicated by the dashed line at 1.0. (E-H) FGF2 and (IL) BMP2 were analyzed as described for VEGF. Data shown in A-C, E-G, and I-K are from a
representative experiment. Each data point represents a single independent culture. Data were
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p<
0.05 vs. GM, $ vs. OM, # vs. TCPS. Data in D, H and L are treatment/control ratios for N = 6
separate experiments and were analyzed using the Mann-Whitney test.
VEGF and FGF2 retained within the microbeads treated with OM were detectable but remained
significantly lower than GM treated groups (Figs. 3A - 3H). A similar reduction was observed in
the VEGF and FGF2 levels retained within microbeads treated with OM-aa., and GM+d
compared to microbeads treated with GM. Removing dexamethasone from OM resulted in
VEGF and FGF2 levels similar to those produced by GM treated groups (Figs. 3A – 3G). GM+d
treatment led to a similar reduction in VEGF and FGF2 as observed with OM treatment (Figs.
3C, 3G). BMP2 levels retained by microbeads cultured in OM, OM-aa, and OM-aa-d were
similar (Fig. 3J) however, a 3 fold increase was observed in OM-d treated groups compared to
groups treated with OM (Figs. 3J, 3K). Although significantly higher levels of BMP2 were
retained within microbeads treated with OM (Fig. 3I), a treatment over control analysis showed
the BMP2 levels retained within microbeads are not significantly different between GM and OM
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groups (Fig. 3L).

Figure 4.3: (A) VEGF retained within the microbeads of microencapsulated rASCs after 5 days of
culture in GM or OM. (B) Effect of removing ascorbic acid (aa) or dexamethasone (d) from OM
on factor retention by microencapsulated rASCs after 5 days in GM, OM, OM-aa, OM-d, OM-aad for 5 days. (C) Effect of dexamethasone on factor retention by microencapsulated rASCs
cultured in GM, GM+d, OM, or OM-d for 5 days. (D) Effect of OM v. GM on VEGF, FGF2, and
BMP2 in retained in rASC microbeads. GM values are indicated by the dashed line at 1.0. (E-H)
FGF2 and (I-L) BMP2 were analyzed as described for VEGF. Data shown in A-C, E-G, and I-K
are from a representative experiment. Each data point represents a single independent culture.
Data were analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s
t-test. * p< 0.05 vs. GM, $ vs. OM, # vs. TCPS. Data in D, H and L are treatment/control ratios
for N = 6 separate experiments and were analyzed using the Mann-Whitney test.
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OM treatment of cells grown on TCPS and in microbeads caused a decrease in Vegfa expression.
Rat osteoblasts expressed similar levels of Vegfa as rASCs on TCPS cultured in GM (Fig. 4A).
Vegfa mRNA levels (Figs. 4A - 4C) decreased after OM, OM-aa, and GM+d treatment and was
restored when dexamethasone was removed from the media. While OM did not reduce Fgf2
expression in monolayer ASCs, it did reduce expression in the microencapsulated ASCs (Fig. 4D).
Deletion of dexamethasone from OM or addition to GM increased expression of this factor (Figs.
4E, 4F). Tgfb1 expression was also decreased in microencapsulated ASCs but not affected in
monolayer cultures (Fig. 4G). Deletion of dexamethasone from OM increased Tgfb1 expression
but

addition

of

dexamethasone

to

GM
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had

no

effect

(Figs.

4H,

4I).

Figure 4.4: (A) Vegf expression in monolayer cultures of rASCs and microencapsulated ASCs
cultured for 5 days in GM and OM. Monolayer cultures of rat osteoblasts grown in their respective
media for 5 days are shown for comparison. (B) Effect of removing ascorbic acid (aa) or
dexamethasone (d) from OM on Vegf expression by microencapsulated rASCs after 5 days in GM,
OM, OM-aa, OM-d, OM-aa-d for 5 days. (C) Effect of dexamethasone on expression by
microencapsulated rASCs cultured in GM, GM+d, OM, or OM-d for 5 days. (D-F) expression of
Fgf2 and (G-I) Tgfb1 were analyzed as described for VEGF. Data shown are from a representative
experiment. Each data point represents a single independent culture. Data were analyzed using
one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. GM, $
vs. OM, # vs. TCPS.
Bmp2 mRNA levels of rASCs grown on TCPS increased with OM treatment, however the
opposite was observed in microencapsulated groups (Fig. 4.5A). Removal of dexamethasone from
OM reversed the OM inhibition of Bmp2 expression in the microencapsulated cells (Fig. 4.5B)
but addition of dexamethasone to GM inhibited Bmp2 expression (Fig. 4.5C). Expression of the
BMP2 antagonist Grem1 was unaffected in monolayer cultures whereas it was blocked in
microencapsulated ASCs (Fig. 4.5D). Removal of dexamethasone removed the OM inhibition of
Grem1 expression but addition of dexamethasone to GM had no effect (Figs. 4.5E, 4.5F).
Expression of Nog was increased more than 3-fold in monolayer cultures treated with OM but it
was reduced by 50% in cultures of microencapsulated ASCs (Fig. 4.5G).

Removal of

dexamethasone from OM restored expression to GM levels (Fig. 4.5H) but addition of
dexamethasone to GM had no effect.
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Figure 4.5: (A) Bmp2 expression in monolayer cultures of rASCs and microencapsulated ASCs
cultured for 5 days in GM and OM. Monolayer cultures of rat osteoblasts grown in their respective
media for 5 days are shown for comparison. (B) Effect of removing ascorbic acid (aa) or
dexamethasone (d) from OM on Bmp2 expression by microencapsulated rASCs after 5 days in
GM, OM, OM-aa, OM-d, OM-aa-d for 5 days. (C) Effect of dexamethasone on expression by
microencapsulated rASCs cultured in GM, GM+d, OM, or OM-d for 5 days. (D-F) expression of
Grem1 and (G-I) Nog were analyzed as described for VEGF. Data shown are from a representative
experiment. Each data point represents a single independent culture. Data were analyzed using
one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. GM, $
vs. OM, # vs. TCPS.
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VEGF and BMP2 secreted into the conditioned media were differentially regulated by OM and by
dexamethasone. OM reduce secretion of VEGF and BMP2 by microencapsulated rat ASCs;
VEGF was restored to GM levels by dexamethasone removal but BMP2 was unaffected (Figs. 6A,
6B). Secretion of neither factor was affected by OM or by OM-d in cultures of microencapsulated
rabbit ASCs (Figs. 6C, 6D). VEGF secretion was blocked by OM in cultures of microencapsulated
mouse ASCs and partially restored by removal of dexamethasone (Fig. 6E), but OM completed
blocked secretion of BMP2 and dexamethasone removal had no effect on this inhibition (Fig. 6F).
For all three human donors, OM reduced secretion of VEGF and deletions of dexamethasone
restored secretion to GM levels but BMP2 in conditioned media was either not detected or was not
affected by OM or OM-d (Figs. 6G - 6I). Variability was also observed for factors retained within
the microbeads. VEGF retained in the rat microbeads was inhibited by OM and restored to GM
levels by removing dexamethasone from OM (Fig. 6M). BMP2 in the microbeads was low in
cultures grown in GM and OM had no effect, but removal of dexamethasone from OM caused a
marked increase in BMP2 in the microbeads (Fig. 6N). OM and OM-d had no effect on VEGF or
BMP2 in microbeads containing rabbit ASCs (Figs. 6O, 6P). VEGF was reduced by OM in
microbeads containing mouse ASCs and was increased by removing dexamethasone from the
medium (Fig. 6Q). No effects of media were observed in mouse microbead BMP2 (Fig. 6R).
Microbeads containing human ASCs all exhibited reduced VEGF when cultured in OM, which
was restored to GM levels by removal of dexamethasone, but no effect of media on BMP2 content
was observed (Figs. 6S - 6X).
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Figure 4.6: Comparison of VEGF and BMP2 in the conditioned media microencapsulated ASCs
and retained within the microbead after 5 days of culture in GM, OM or OM-d. Microbeads
containing rASCs, New Zealand white rabbit ASCs, C57bl/6 mouse ASCs, or human ASCs from
three donors were examined. (A–F) VEGF in conditioned media. (G-L) BMP2 in conditioned
media. (M-R) VEGF in microbeads. (S-X) BMP2 retained within microbeads. Data shown are
from a single representative experiment. Each data point represents 6 independent cultures. Data
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were analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test.
* p< 0.05 vs. GM, $ vs. OM.
4.4 Discussion
This study demonstrates that production of growth factors and other regulatory molecules
by microencapsulated ASCs is sensitive to the culture medium used and is different from
production by monolayer cultures over the same time period and in the same media. The effects
of both culture media and microencapsulation vary with the factor being examined. In some cases,
regulation occurs at the expression level. There is additional regulation due to the differential
retention of proteins within the alginate bead or released into the conditioned media. Importantly,
our results show that deletion or addition of individual media components can have a marked effect
on expression, retention, and release of both VEGF and BMP2. Finally, our results suggest that
species differences may exist. Our data indicate that microencapsulation modifies production of
some, but not all factors. When rASCs were cultured in MSC growth medium, comparable levels
of VEGF and FGF2 were present in the conditioned media of monolayer cultures and
microencapsulated cells. In contrast, the conditioned media of microencapsulated rASCs had
higher levels of BMP2 than monolayer cultures. Higher production of BMP2 by
microencapsulated cells may be due to the microenvironment present in the 3D system of the
microbeads, including cues related to cell shape [49]. MSCs in monolayer culture are flattened and
spread in contrast to cells within the alginate hydrogel, which are spherical [50]. Other studies
have shown that cytoskeletal arrangement can have profound effects on BMP2 gene expression
and protein synthesis [51].
Oxygen tension within the microbead environment may also play a role. Others have
shown a positive relation between hypoxia and BMP2 production [52, 53]. A study with
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endothelial cells under hypoxia resulted in a 2-fold to 3-fold increase in Bmp2 expression [52].
We did not measure differences in oxygen tension within the bead in the present study. In previous
work, we showed that microencapsulated ASCs generated angiogenic factors including VEGF and
FGF2 both in vitro and in vivo [37, 48]. This would suggest that the cells within the beads are in
a hypoxic environment. However, in the present study while we observed a marked increase in
Vegf expression and noted Fgf2 expression, but we did not observe increased VEGF production
by encapsulated ASCs compared to monolayer ASCs, nor did we detect FGF2 production.
Moreover, expression and production of VEGF and FGF2 were decreased when the
microencapsulated ASCs were incubated in OM. This was not due to a reduction in cell number
as DNA content of the cultures was not affected by the difference in medium. Osteoblasts in a
hypoxic microenvironment have been shown to produce VEGF, but osteoblast differentiation does
not appear to be responsible for the results[53]. Although BMP2 was increased in cultures grown
in OM, suggesting osteogenic differentiation of the cells, the decrease in VEGF and FGF2 argued
against the hypothesis that significant differentiation had occurred under the conditions of the
experiment.
This led us to consider if specific components of the OM might be responsible. We focused
on two differentiation cues in OM: ascorbic acid 2-phosphate and dexamethasone [54, 55]. Our
results showed that removing ascorbic acid 2-phosphate did not alter any of the parameters tested
in the study. In contrast, removal of dexamethasone stimulated expression of Vegfa, Fgf2, Tgfb1,
and Bmp2 as well as its inhibitors Grem1 and Nog. There was a corresponding increase in VEGF
and FGF2, but not of BMP2 in the conditioned media of the microbead cultures. When we added
dexamethasone to GM, we observed comparable effects on expression and protein to OM-treated
microbeads, validating the conclusion that dexamethasone was a key player in modulating
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production of angiogenic factors, as has been shown by others [56]. Although dexamethasone
inhibited expression and production of angiogenic factors in our study, Mostafa et al. demonstrated
the importance of dexamethasone on the differentiation of stem cells along the osteogenic lineage
and specifically, for the mineralization of cells [57]. It has also been shown that dexamethasone
induces osteogenesis via Runx2 upregulation [58].
One explanation for the differences in our study with those reported in the literature is the
experimental design. We examined effects on microencapsulated cells, not monolayer cultures as
has been done previously. This may have altered the threshold concentration of dexamethasone
needed to trigger differentiation. The reported dose of dexamethasone in the literature is 10 nM,
[59] which is similar to the dexamethasone concentration in Lonza OM, suggesting that a different
optimal dexamethasone concentration may exist for microencapsulated rASCs.
Time course of exposure is also a consideration. Whereas Bmp2 expression was reduced
in microbeads cultured in OM compared to GM, it was increased by removal of dexamethasone
from OM. Despite the increase in expression, BMP2 was not increased in the conditioned media
of OM-d cultures. However, BMP2 was increased in the microbead itself. This suggests that
protein production was stimulated but the rate of BMP2 diffusion through the microbead hydrogel
was not as efficient as for VEGF or FGF2. Whether this was due to differential affinities of these
factors for alginate or to differences in rate of synthesis was not examined.Our data support the
conclusion that the overall effect of OM is due to interactions among its components. Removal of
ascorbic acid 2-phosphate by itself did not modify the parameters we tested, but in cultures grown
in media without ascorbic acid 2-phosphate and dexamethasone, the deletion of ascorbic acid 2phosphate mitigated the effects of dexamethasone depletion. Expression of Fgf2 in OM-aa-d
microbeads was double that seen in OM-d and was increased over levels in GM cultures. In
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contrast, expression of Tgfb1 was 40% lower in OM-aa-d microbeads compared to OM-d
microbeads. Bmp2 and Grem1 in OM-aa-d microbeads were more than 50% lower than OM-d
microbeads but Nog was unaffected. Under the conditions of our study, we did not see a
corresponding effect of ascorbic acid deletion on levels of VEGF, FGF2 or BMP2 in the
conditioned media, but we did observe a 50% reduction in the amount of BMP2 retained in the
microbead, supporting our hypothesis that the hydrogel properties are important considerations in
determining the overall effect of medium composition on outcomes. Beta-glycerophosphate has
been shown by others [60] to regulate osteoblastic differentiation of MSCs. It should be noted that
we did not modify the beta-glycerophosphate content of the OM, so all of our observations are in
the context of this important media component being present.
Our results also showcase potential differences in outcomes dependent on the source of
ASCs. Microencapsulated ASCs from New Zealand white rabbits did not exhibit reduced VEGF
in OM, nor did they show enhanced VEGF when cultured in OM-d. Microencapsulated C57Bl/6
mouse ASCs did not exhibit increased retention of BMP2 within the alginate hydrogel in OM-d
media although they did respond similarly to Sprague Dawley rat microbeads to OM-d treatment
with respect to BMP2 content of the conditioned media. Moreover, within species variation exists
as well. Microbeads containing ASCs from three different human donors had similar responses to
GM, OM, and OM-d, with one significant exception: production of BMP2. The findings support
use of caution in making definite statements concerning complex cell populations typically present
in ASC preparation.
4.5 Conclusions
Microencapsulated rASCs are able to produce osteogenic and angiogenic factors. The
expression, production, secretion and retention of these factors are dependent on the culture media
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used and on properties of the alginate hydrogel. Dexamethasone is a key factor in OM that
regulates angiogenic factor production. In addition, factor production differs among species as
well as among individual donors. Therefore, local factor production by microencapsulated ASCs
can play an important role in bone regeneration. In the case of clinical applications, pre-screening
of human donors would be recommended for their ASCs.
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CHAPTER 5
The Development of a Degradable Alginate Microbead System for Bone
Regeneration
Summary
Cell-based therapies have potential for tissue regeneration but poor delivery methods lead
to low viability or dispersal of cells from target sites, limiting clinical utility. Here, we developed
a degradable and injectable hydrogel to deliver stem cells for bone regeneration. Alginate
microbeads <200µm are injectable, persist at implantation sites and contain viable cells, but do not
readily degrade in-vivo. We hypothesized that controlled release of rat adipose-derived stem cells
(ASCs) from alginate microbeads can be achieved by incorporating alginate-lyase in the hydrogel.
Microbeads were formed using high electrostatic potential. Controlled degradation was achieved
through direct combination of alginate lyase and alginate at 4°C. Results showed that microbead
degradation and cell release depended on the alginate lyase to alginate ratio. Viability of released
cells ranged from 87% on day 2 to 71% on day 12. Monolayer cultures of released ASCs grown
in osteogenic medium produced higher levels of osteocalcin and similar levels of other soluble
factors as ASCs that were neither previously encapsulated nor exposed to alginate lyase. Bmp2,
Fgf2, and Vegfa mRNA in released cells were also increased. Thus, this delivery system allows
for controlled release of viable cells and can modulate their downstream osteogenic factor
production.
5.1. Introduction
Approximately 5 to 20% of the total bone fractures that occur yearly fail to heal completely
resulting in a nonunion [1]. Treatment frequently involves resection of the nonunion tissue and use
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of grafts augmented with autologous bone marrow. One of the factors contributing to non-union
is the loss of multipotent stem cells capable of differentiating along the osteoblast lineage [61].
Injectable, cell-based therapies could be especially advantageous for these patients since they are
less invasive than current surgical treatments and could aid in bone regeneration. Adipose-derived
stem cells (ASCs), which are multipotent [2], are easily isolated, and can be induced to express an
osteoblastic phenotype [36]. Recent reports indicate that ASCs are not as osteogenic as bone
marrow stem cells, but their ready availability supports their use as a potential cell source [62].
One notable disadvantage of cell based therapies is that injected cells tend to disperse to
tissues other than the intended site [3]. Moreover, those cells that do home to the intended site may
not remain viable over a sufficient period of time or differentiate into the desired phenotype. This
is particularly problematic in tissues like fracture non-unions, where vasculature is often not well
developed. Therefore, the goal of this study was to develop a system of injectable hydrogels that
would allow ASCs to remain viable at the injury site, maintain their ability to differentiate along
the osteoblast lineage, and be released after a given time period.
Alginate hydrogels have gained special attention because of their ability to provide a
temporary support for a variety of cell types [63-65] while facilitating the transport of nutrients,
gases and metabolic wastes [66]. Alginate microbeads have been used to deliver insulin secreting
cells for insulin dependent diabetes [28], parathyroid glands for hypoparathyroidism [29], and stem
cells for organ repair [30]. Furthermore, alginate hydrogels can be modified to incorporate specific
biochemical cues [24, 67]. Alginate is a block copolymer that consists of (1-4)-linked-β-D
mannuronic acid (M units) and α-L-guluronic acid (G units) monomers, where each block may be
repeating M units (poly (M)) or G units (poly(G)) or a random organization of M and G units
(poly(MG)) [27]. It is present in the cell walls of brown algae and can also be synthesized by
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bacteria. The advantage of alginate compared to synthetic polymers is its ability to form a hydrogel
under relatively mild pH and temperature, and its ability to be sterilized [27]. Alginate forms a
hydrogel once it is cross-linked between the G units of neighboring chains with divalent cations
such as Ca++ or Ba++.
When ASCs are encapsulated using an electrostatic potential in a calcium crosslinking
solution containing glucose as an osmolyte, the resulting microbeads contain a tunable number of
cells in a bead diameter of 200µm . These microbeads were used successfully as a delivery vehicle
for subcutaneous injection of ASCs in mice and the cells remained viable for two months [4, 5].
Mass transfer issues are obviated due their small size and high surface to volume ratio. These
studies have also shown that encapsulated ASCs can be induced to express a chondrocytic
phenotype and to produce chondrogenic factors, suggesting that similar approaches will be
successful for bone regeneration [48, 68].
Despite the many advantages of alginate, a central challenge remains – alginate does not
degrade enzymatically within the human body and non-enzymic breakdown occurs very slowly.
In vitro, release of cells is achieved by chelating Ca++, thereby breaking the crosslinks between
chains. There have been attempts to control the rate of degradation of alginate constructs in vivo
by decreasing the molecular weight through oxidation and γ-irradiation, thus inducing
hydrolytically labile groups [6]. After six months, these constructs maintained their structure but
elastic modulus was decreased and cell migration was increased. Another approach involved the
encapsulation of poly(lactide-coglycolide) (PLGA) particles loaded with alginate lyase [69], an
enzyme that cleaves the β-1,4-glycosidic linkage between the monosaccharide units of the alginate
through a β-elimination reaction producing uronate products [26]. Finally another strategy used
covalent crosslinking with bifunctional groups to degrade alginate constructs [70]. These efforts
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have been partially successful in larger alginate constructs (4mm), but there are no methods to
control the degradation of smaller alginate microbeads (200µm – 500µm), which are important for
injectable applications.
In the present study, we focused on developing a system of injectable hydrogels to allow
the cells to remain at the area of injury, and secrete soluble factors that facilitate bone regeneration.
We hypothesized that controlled degradation of alginate microbeads can be used to control the
release kinetics of viable cells for regeneration. Our objectives were to (i) develop and optimize a
method of incorporating alginate lyase in alginate microbeads; (ii) establish controlled degradation
parameters using medical grade alginate; (iii) determine if alginate lyase-mediated alginate
degradation has an effect on the viability and phenotype of the released cells; (iv) determine if
alginate microbeads containing alginate lyase degrade in vivo; and (v) identify if the degradation
by-products are toxic and elicit an inflammatory response.
5.2. Methods
5.2.1 Alginate Degradation
To test our hypothesis that time controlled degradation can be achieved by the
incorporation of alginate lyase into alginate microbeads, various ratios of alginate lyase (units [U]
of enzyme activity) to alginate [g] were combined to form microbeads. Two types of alginates
were used: “wound healing” grade alginate (55% to 60% mannuronate units) (Protonal®
LF10/60LS, FMC BioPolymer, Sandvika, Norway) and medical grade alginate (50% mannuronate
units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC BioPolymer). Low viscosity
alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a concentration of
40 mg/ml. Microbeads were created using a Nisco Encapsulator VAR V1 LIN-0043 (Nisco
Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle with an inner diameter of
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0.175 mm (0.12 mm for microbeads used in the in vivo study), an electrostatic potential of 6 kV
and a calcium crosslinking solution. The crosslinking solution contained 75 mM CaCl2, 90 mM
glucose with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 (Sigma
Aldrich) (HEPES-buffered) [70]. Alginate microbeads were allowed to crosslink for an additional
10 minutes, washed with 0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, and
suspended in saline supplemented with calcium chloride (1.8 mM Ca2+).
Two methods were used to incorporate alginate lyase (28000 U/g, Sigma Aldrich, St.
Louis, MO) into the microbeads. Initially, the enzyme was first packaged in polylactide-coglycolide (PLGA 50:50) (Sigma Aldrich) particles at a w/w ratio of alginate lyase to PLGA of
1:10. The particles were made using the solid in oil in water method as previously described [69].
The PLGA particles were then incorporated into alginate microbeads by encapsulating 1mg PLGA
particles to 70 mg alginate. Once the beads were made they were suspended in saline with
physiological levels of calcium (1.8 mM Ca2+) at 370C. However this approach did not prove to
be successful in degrading the alginate beads.
Alternatively, alginate lyase was incorporated into alginate microbeads by combining
equal volumes of 4% low viscosity, high mannuronate (LVM) alginate and a known concentration
of alginate lyase solution in 0.9% (w/v) saline. Prior to the combination, both components were
kept at 4°C. The final 2% (w/v) alginate was mixed at 1000 rpm for one minute. A series of
degradation experiments were done with various ratios of alginate lyase to alginate to achieve the
optimal ratios that resulted in controlled degradation over 12 days. The final gradient was 14 U/g
to 0.35 U/g for experiments assessing alginate degradation in the absence of cells and 1.4 U/g to
0.09 U/g for experiments assessing degradation in the presence of cells. Prior to assessing
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degradation in the presence of cells, experiments assessing alginate degradation in mesenchymal
stem cell growth medium (MSCGM, Lonza Biosciences, Walkersville, MD) were performed.
Microbead degradation was monitored by measuring the absorbance of the uronate
products in optically clear 96-well plates (UV-Star® Microplate, Greiner Bio One, Frickenhausen,
Germany) at 235nm by using a Synergy H4 Hybrid Reader (BioTek, Winooski, VT) [71] every 48
hours. In addition, the diameter of the microbeads was measured every 48 hours over the 12 day
period using images taken with a Leica DMIL microscope connected to a Leica DC 300 camera
(Leica, Solms, Germany) and analyzed with Image-Pro Plus software (version 4.5.1.22, 2002,
Media Cybernetics, Rockville, MD). The light microscope was used to follow the alginate
microbead degradation and cell release from the alginate microbeads. At each time point one image
per field was taken for each group.
5.2.2 Adipose Derived Stem Cells
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [2, 36], under an
Institutional Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute
of Technology. Briefly, the inguinal fat pad was removed and transferred to a container with
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3%
sterile-filtered L-glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with
Hank’s balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) for 30 minutes on a rocker at 37°C. Following
trypsinization, the supernatant was discarded. Adipose tissue was cut into small pieces and
incubated in a digestive cocktail containing collagenase type I (365 units/mL) (Sigma Aldrich) and
dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours. After incubation, the oily upper layer
was removed and the digest was quenched with an equal amount of MSCGM. The cells were
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separated, plated in T-175 flasks at 5,000 cells/cm2 and cultured in MSCGM at 37 °C and 5% CO2.
For the next two days the monolayers were washed with Dulbecco’s phosphate buffered saline
(DPBS) (Invitrogen) and fed with MSCGM every 24 hours. Thereafter media were changed every
48 hours and cells were cultured to confluence. First passaged cells were used for studies.
ASCs were also isolated from green fluorescent protein (GFP) positive rats (Rat Resource
and Research Center, Columbia, MO) under IACUC approval and cultured up to passage 6 for the
cell release studies.
5.2.3 Cell Release Studies
To test our hypothesis that controlled release of cells can be achieved through the
controlled degradation of alginate microbeads, ASCs were encapsulated in various ratios of
alginate lyase to UV-sterilized medical grade alginate. ASCs were released from the culture plate
by trypsinization, and collected by centrifugation after rinsing the cell pellet with MSCGM, the
cells were suspended in the alginate lyase/alginate mixture at a concentration of 25 x 106 cells/ml.
Alginate microbeads were then formed as previously described. Microencapsulated ASCs and
GFP-ASCs were suspended in 40µm cell strainers (BD Falcon, Franklin Lakes, NJ) and cultured
in MSCGM in non-tissue culture treated 6-well plates to limit proliferation of released cells in the
well. Media were changed every 48 hours and each cell strainer was washed twice with 0.9% (w/v)
saline to ensure that all the cells released were collected. Additional cells on the plate’s surface
were collected through trypsinization.
5.2.3.1 Cell Number
The number of cells released was counted using a Z1 particle counter (Beckman Coulter,
Brea, CA). For the groups where the alginate microbeads did not fully degrade by the end of the
12 day period, 82.5 mM sodium citrate was used to release the remaining cells. All cells were
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collected, suspended in 0.05% Triton-X100 (Sigma Aldrich) and used to determine the DNA
content [Quant-iT™ Picogreen® ds DNA Reagent, Invitrogen, CA] and alkaline phosphatase
specific activity. The percent cell release was calculated as a function of the total number cells in
the 0 U/g group (control), which reflected any change due to proliferation or cell death over the
incubation period. The total number of cells microencapsulated in the control group was
determined by the number of cells released on the 12th day using 82.5 mM sodium citrate.
To determine if our observations were applicable to other cell types, microbeads were
prepared containing human osteoblast-like MG63 cells (American Type Culture Collection,
Rockville, MD). Microbeads were cultured in DMEM supplemented with 10% fetal bovine serum
(FBS; Gibco, Carlsbad, CA) and 1% penicillin-streptomycin.
5.2.3.2 Alkaline Phosphatase Specific Activity
To measure alkaline phosphatase specific activity, released cells were suspended in 0.05
% Triton-X100 and lysed by sonication. Enzyme activity was measured as the ability to convert
p-nitrophenylphosphate to p-nitrophenol at pH 10.2. This was normalized by the total protein
content (Pierce Macro BCA Protein Assay kit, Pierce Biotechnology, Rockford, IL) in the cell
lysate.
5.2.3.3 Cell Viability
5.2.3.3.1 LIVE/DEAD Assay
Viability of cells within microbeads and of cells released from the microbeads (released
cells) was measured using a LIVE/DEAD Viability kit (Invitrogen). Samples (200µl) were
collected at each time point (days 0, 2, 4, 6, 8, 10, and 12) for microbeads without alginate- lyase
and on the days where the greatest cell release occurred for the microbeads incorporating alginate
lyase. The 200µl aliquots were transferred to a chamber slide and incubated for 30 minutes at 37°C
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in 0.9% saline containing 4μM ethidium homodimer-1 and 2μM calcein-AM. Images were
obtained using a Zeiss LSM 700-405 confocal microscope (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY). Three images were obtained for each well and then red and green cells were
counted using Image-Pro Plus software (Media Cybernetics) to determine the percent viability.
5.2.3.3.2 TUNEL Assay
To determine the number of cells going through apoptosis, the integrity of the cell’s DNA
was measured using the TiterTACS™ Apoptosis Detection Kit following the manufacturer’s
protocol (Trevigen, Gaithersburg, MD). At each time point, 300,000 cells from each well were
used for the assay.
5.2.4 Phenotype of Released ASCs
For these experiments ASCs that were never microencapsulated or exposed to alginate
lyase were compared to ASCs released from microbeads containing either 0 U/g or 0.13 U/g
alginate lyase. To investigate the osteogenic potential of the released cells, ASCs were collected
at day 8 from the 0 U/g and 0.13 U/g groups, were plated at 5000 cells/cm2 and cultured in
MSCGM until confluent. ASCs that were never microencapsulated or exposed to alginate lyase
were also cultured in MSCGM until confluent. Both cell types were treated with OM for 7 days
followed by MSCGM for 24 hours.
5.2.4.1 Alkaline Phosphatase Specific Activity
Alkaline phosphatase specific activity was measured as described in 5.2.3.2.
5.2.4.2 Soluble Factor Quantification
Enzyme-linked immunosorbent assays (ELISA) were used to measure the levels of bone
morphogenetic protein-2 (BMP2), fibroblast growth factor-2 (FGF2), osteoprotegerin (OPG), and
vascular endothelial growth factor (VEGF) (R&D Systems, Minneapolis, MN) in the conditioned
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medium. The levels of osteocalcin were measured with a radioimmunoassay kit (Human
Osteocalcin RIA Kit, Biomedical Technologies, Stoughton, MA). All ELISAs and the
radioimmunoassay were normalized by the DNA content of the cells.
5.2.4.3 RNA Extraction and Real Time PCR
RNA was extracted 8 hours after the last medium change using TRIzol ® [Invitrogen] and
quantified with the Nanodrop Spectrophotometer (Thermo Scientific, Waltham, MA). Samples
were then converted into cDNA by the reverse transcription of 1 µg RNA with random primers
(Applied Biosystems, Warrington, UK) and Multiscribe Reverse Transcriptase (Applied
Biosystems). The cDNA was analyzed for mRNA levels by real-time PCR using the StepOne Plus
PCR System (Applied Biosystems). mRNA levels for the following proteins were measured;
BMP2 (Bmp2), type I collagen (Col1), FGF2 (Fgf2), Osterix (Osx), Runx2 (Runx2), osteocalcin
(Ocn), and VEGF-A (Vegfa). In addition the mRNA levels for BMP antagonists, Noggin (Nog)
and Gremlin 1 (Grem1) were measured. All primers (Table 5.1) were designed using the Beacon
Designer 7.0 program and then synthesized by the Eurofins MWG Operon (Huntsville, AL). The
mRNA levels were quantified relative to a standard curve of known concentration, and results
were normalized to the transcript levels of the housekeeping gene, 40S ribosomal protein S18
(Rps18).
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Table 5.1. Primer sequences used for the analysis of mRNA levels.
Gene

Forward Primer

Reverse Primer

Bmp2 TGT GAG GAT TAG CAG GTC TTT G
CTT CCG CTG TTT GTG TTT GG
Col1
CGA GTA TGG AAG CGA AGG
AGT GAT AGG TGA TGT TCT GG
Fgf2
Qiagen QuantiTect Primer 00189035
Grem1 AAG CAC ATC ACC GGC CAA CGG ATC AGC GAC AGA CGG GGC ATC T
Nog
GCC AGC ACT ATC TAC ACA TCC
CAG CAG CGT CTC GTT CAG
Ocn
Qiagen QuantiTect Primer 01084573
Osx
Qiagen QuantiTect Primer 01083082
Rps18
TCG CTA TCA CTG CCA TTA AGG
TGT ATT GTC GTG GGT TCT GC
Runx2
TCC CCA TCC ATC CAT TCC
AGA GGC AGA AGT CAG AGG
Vegfa
GGA CAT CTT CCA GGA GTA CC
TCC AGG GCT TCA TCA TTG C

5.2.6 Alginate Microbead Degradation In Vivo
In vivo studies were done to examine if alginate microbeads incorporating alginate lyase
would degrade and determine if the degradation by-products results in an inflammatory response.
Male C57 Black 6 mice were handled under a protocol approved by the IACUC at the Georgia
Institute of Technology. Prior to surgeries, mice were anesthetized using isoflurane gas. Alginate
microbeads (0.1 ml) with and without alginate lyase (1.75 U/ml and 0 U/ml) but without cells were
injected subcutaneously in the dorsal side using a 16 gauge needle [4]. Each animal received 1
injection subcutaneously (n = 6 for each experimental condition). Animals were euthanized by
CO2 inhalation after 2 weeks and a portion of the skin removed and processed for histology as
described below.
5.2.6.1 Histology
After 48 h of fixation in formalin, samples were dehydrated in a series of 95% and 100%
ethanol and xylene washes. Samples were embedded in paraffin, and cut into 8-μm thick sections
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(Shandon Finesse 325, Thermo Scientific). The sections were stained with haematoxylin and eosin,
and then imaged with a Leica DMLB microscope (Leica Microsystems, Bannockburn, IL).
5.2.7 Statistical Analysis of Data
The results of the quantitative and morphometric analyses were calculated as the means ±
SEM of six independent cultures per variable. Statistically significant differences between groups
were determined by one-way ANOVA followed by Bonferroni’s modification of Student’s t-test.
P values ≤ 0.05 were considered significant. All experiments were repeated at least twice to ensure
validity of results. Data presented are from representative experiments.
5.3 Results
5.1 Controlled Degradation of Alginate Microbeads
Controlled degradation of alginate microbeads made from both “wound healing” (Fig. 5.1)
and medical grade (Fig. 5.2) alginate was a function of alginate lyase concentration. For both
alginate types, as the ratio of alginate lyase to alginate increased, the time required for total
degradation of the alginate microbeads decreased (Figs. 5.1A and 5.2A). Complete degradation
was not observed in microbeads produced using 0.7 U/g in either alginate formulation over the 12
day time course. Degradation of the wound healing grade alginate (28 U/g) occurred within 4 days
(Fig. 5.1B) whereas degradation of the medical grade alginate (14 U/g) required 6 days (Fig. 5.2B).
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Figure 5.1: Degradation of alginate (wound healing grade) microbeads with different formulations
of alginate lyase (U): alginate (g). (A) Visualization of alginate microbead degradation under an
inverted light microscope (mag. = 10x), (B) absorbance of uronate products, and (C) diameter of
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beads as they degrade over the 12 day period. Data were analyzed using one-way ANOVA
followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 0.
Microbead diameter changed overtime in an enzyme-dependent manner that was
formulation specific. Newly generated microbeads had an average diameter of 400µm when placed
in the degradation solution (saline with 1.8mM Ca2+). Incorporation of 28 U/g alginate-lyase
caused wound healing grade alginate bead diameters to decrease by >100µm within 2 days. In
contrast microbeads containing 0.7 U/g did not decrease significantly until day 12. There were no
changes in diameter in the absence of enzyme (Fig. 5.1C). Similarly, medical grade alginate beads
did not change size in the absence of enzyme (Fig. 5.2C). However, diameters increased by 100µm
in the presence of alginate lyase and this effect occurred more rapidly at higher enzyme
concentrations.
Degradation of the medical grade alginate microbeads with no cells in MSCGM (data not
shown) occurred faster compared to the same microbeads suspended in saline supplemented with
physiological levels of calcium (1.8 mM Ca2+) (Fig. 5.2D).
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Figure 5.2: Degradation of alginate (medical grade) microbeads with different formulations of
alginate lyase (U): alginate (g). (A) Visualization of alginate microbead degradation under an
inverted light microscope (mag. = 10x), (B) absorbance of uronate products, (C) diameter of beads,
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and (D) diameter of beads in MSCGM as they degrade over the 12 day period, Data were analyzed
using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 v.
day 0.
5.3.2 Release of Cells
Cell release kinetics varied as a function of alginate lyase content (Fig. 5.3A). Medical
grade alginate microbeads with the highest concentration of alginate lyase (1.4 U/g) released the
cells in the shortest period of time (2 days) (Fig. 5.3B). A similar result was seen in the percent
release where the highest percentage of cells (63%) was released on day 2 from the 1.4 U/g
microbeads (Fig. 5.3C). DNA content of the released cells confirmed these observations (Fig.
5.3D). Released cells had measureable alkaline phosphatase specific activity (Fig. 5.3F). The
highest levels of enzyme activity were seen in cells that were encapsulated in beads with alginate
lyase content varying from 0.09 to 0.24 U/g. Similar cell release kinetics were observed using
GFP-ASCs (Figs. 5.4A and 5.4B), and confirmed by measuring fluorescence (Fig. 5.4C). Release
of MG63 cells exhibited comparable kinetics (Figs. 5.4D and 5.4E). Unlike the ASCs, however,
alkaline phosphatase specific activity of the released MG63 cells was low and did not vary with
alginate lyase content of the microbeads (Fig. 5.4F).
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Figure 5.3: Release of ASCs from alginate (medical grade) microbeads with different formulations
of alginate lyase (U): alginate (g) over a 12 day period. (A) Visualization of the released ASCs
from alginate microbeads under an inverted light microscope (mag. = 10x), (B) the number of
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released ASCs, (C) percent cell release, (D) total DNA content of the released cells, and (E) total
alkaline phosphatase in the cell lysate. Data were analyzed using one-way ANOVA followed by
Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 2.

Figure 5.4: Release of GFP-conjugated ASCs and MG63 osteoblast-like cells from alginate
(medical grade) microbeads with different formulations of alginate lyase (U): alginate (g) over 12
days. Top row – GFP-ASCs: (A) the number of released cells, (B) total DNA content, and (C)
fluorescence. Bottom row – MG63 cells: (D) the number of released cells, (E) total DNA content,
and (F) total alkaline phosphatase in the cell lysate. Data were analyzed using one-way ANOVA
followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. day 2.
5.3.3 Effect of Alginate lyase Mediated Degradation on Viability of Released Cells
Live/dead staining demonstrated that ASCs microencapsulated in alginate without alginate
lyase remained viable throughout the culture period (Fig. 5.5A). On day 2, 64% of the cells were
viable and on day 12, 79% were viable (Fig. 5.5B). The cells released from the microbeads
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remained viable throughout the 12 days (Fig. 5.6A), ranging from 87% on day 2 to 71% on day 12
(Fig. 5.6B). As the cells were released they were not in the process of apoptosis (Fig. 5.6C).

Figure 5.5: Viability of ASCs in microbeads without alginate lyase. (A) Live/dead staining of
ASCs within the 0 U/g alginate (medical grade) microbeads (Scale bar = 50 µm) on days 2, 4, 6,
8, 10, and 12, where green represents live cells and red represents dead cells, and (B) the percent
viable cells. Data were analyzed using one-way ANOVA followed by Bonferroni’s modification
of Student’s t-test. * p < 0.05 vs. day 2.
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Figure 5.6: Viability of ASCs released from alginate (medical grade) microbeads made with
different formulations of alginate lyase (U): alginate (g) (Scale bar = 50 µm) (A) Live/dead staining
of released ASCs, where green represents live cells and red represents dead cells, (B) the percent
viable cells, and (C) TUNEL assay of released ASCs (the horizontal bar represents the positive
control generated) at the respective times; 1.4 U/g on day 2, 0.35 U/g on day 4, 0.24 U/g on days
4 and 6, 0.18 U/g on day 8, 0.13 U/g on day 10, and 0.09 U/g on days 10 and day 12. Data were
analyzed using one-way ANOVA followed by Bonferroni’s modification of Student’s t-test. * p <
0.05 vs. day 2.
5.3.4 Effect of Alginate Lyase Mediated Degradation on Cell Phenotype
Microencapsulation in alginate microbeads containing alginate lyase did not alter the
osteoblast differentiation potential of ASCs.
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When compared to ASCs that were never

encapsulated, the released cells exhibited lower DNA content following culture for 7 days in OM
but there were no differences due to incorporation of alginate lyase in the microbeads (Fig. 5.7A).
Alkaline phosphatase specific activity of the released cells was comparable to that of the never
encapsulated ASCs (Fig. 5.7B). In contrast, ASCs released from the microbeads produced higher
levels of osteocalcin than the never-encapsulated cells, but again, no difference was observed as a
function of alginate lyase content (Fig. 5.7C). Osteoprotegerin content of the conditioned media
was comparable for never-encapsulated ASCs and ASCs released from microbeads containing
0.13 U/g enzyme, whereas cells released from the control microbeads exhibited lower production
of this protein (Fig. 5.7D). None of the ASCs produced detectable VEGF following 7 days culture
in OM, although all ASCs produced FGF2 (Figs. 5.7E, and 5.7F).
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Figure 5.7: The osteogenic potential of ASCs released from alginate microbeads. ASCs that were
not encapsulated (monolayer cells) (M), microencapsulated (µE) and released from 0 U/g and 0.13
U/g alginate (medical grade) microbeads were cultured in osteogenic medium for 7 days, followed
by MSCGM for 24 hours. (A) DNA content, (B) alkaline phosphatase specific activity in the cell
lysate, and levels of the following proteins in the conditioned media: (C) osteocalcin, (D)
osteoprotegerin, (E) vascular endothelial growth factor (VEGF), and (F) fibroblast growth factor
2 (FGF2). Data were analyzed using one-way ANOVA followed by Bonferroni’s modification of
Student’s t-test. * p< 0.05 vs. M.
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mRNA levels were more sensitive to whether the ASCs had been microencapsulated and
the type of microbead. Runx2 (Fig. 5.8A), Osx (Fig. 5.8B), and Col1 (Fig. 5.8C) mRNAs were
comparable in all ASCs. Bmp2 levels were elevated in cells released from the microbeads and
this effect was even greater in cells released from microbeads containing alginate lyase (Fig. 5.8D).
mRNAs for the BMP inhibitors Gremlin-1 and Noggin were also increased in ASCs released from
microencapsulated cells. Whereas Grem1 was highest in cells from microbeads containing
enzyme (Fig. 5.8E), Nog was elevated to a comparable extent in cells that had been
microencapsulated in both types of microbeads (Fig. 5.8F). Vegf was increased in a comparable
manner to Nog (Fig. 5.8G) and Fgf2 was increased in a comparable manner to Grem1 (Fig. 5.8H).
Osteocalcin mRNA was insensitive to the prior experience of the ASCs (Fig. 5.8I).
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Figure 5.8: mRNA expression in ASCs released from alginate microbeads. ASCs that were not
encapsulated (monolayer cells) (M), microencapsulated (µE) and released from 0 U/g and 0.13
U/g alginate (medical grade) microbeads were cultured for 7 days in osteogenic medium, followed
by MSCGM for 8 hours. mRNA’s for (A) runt-related transcription factor 2 (Runx2), (B) osterix
(Osx), (C) type 1 collagen (Col1), (D) bone morphogenetic protein 2 (Bmp2), (E) Gremlin 1
(Grem1), (F) noggin (Nog), (G) vascular endothelial growth factor (Vegfa), (H) fibroblast growth
factor 2 (Fgf2), and osteocalcin (OCN) were measured. Data were analyzed using one-way
ANOVA followed by Bonferroni’s modification of Student’s t-test. * p< 0.05 vs. M.
5.3.5 Alginate Microbeads without Cells Incorporating Alginate Lyase Degrade In Vivo
After two weeks of implantation, microbeads without alginate lyase were present in the
tissue of all animals (Fig. 5.9A). There was no apparent immune response (Fig. 5.9B) and the size
of the beads was not reduced. In contrast, beads that contained alginate lyase were not present
(Figs. 5.9C and 5.9D). There was no immune cell infiltrate in response to the degradation products.
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Figure 5.9: H&E staining of subcutaneous site of alginate microbead implantation after 2 weeks:
(A) alginate microbeads (0 U/g), scale bar represents 500 µm; (B) scale bar represents 200 µm,
arrows indicate alginate microbeads; (C) alginate microbeads incorporating alginate lyase (1.75
U/g), scale bar represents 500 µm, the arrow head indicates the implantation site; and (D) alginate
microbeads incorporating alginate lyase (1.75 U/g), scale bar represents 200 µm. The outlined
black box represents the area magnified 4 times on the right.
5.4. Discussion
Alginate hydrogels used to deliver stem cells must be degradable in vivo to allow for the
release of cells, thus facilitating tissue regeneration. Moreover, the rate of degradation must be
controllable in order to fit the clinical application. In order to achieve controlled degradation, our
first approach incorporated PLGA particles loaded with alginate lyase in alginate microbeads, as
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suggested by Ashton et al. [69]. However this approach did not result in degradation, for a number
of reasons. The loading efficiency of the PLGA particles in the microbeads was low, and the
amount of released enzyme was insufficient to degrade the alginate. The 4 mm diameter constructs
described by Ashton et al. were not only significantly larger than the microbeads used in the
present study, but they were fabricated with 50% less alginate, which leads to lower guluronate
content resulting in a lower cross-linking density. Hydrogel structures with lower mechanical
stability and glycosidc bonds may degrade easily with PLGA loaded with alginate lyase.
Moreover, the high electrostatic potential used to generate the microbeads used in the present study
causes formation of an alginate-rich shell, which may further limit degradation.
The second approach demonstrated that controlled degradation can be achieved by the
incorporation of alginate lyase during microbead production using an electrostatic potential. The
effects of the alginate lyase are concentration dependent. As the amount of incorporated enzyme
is increased, the rate of microbead degradation is increased. This correlation between enzyme
content and alginate degradation was found with two different alginate formulations used in
medical applications but there were some differences. Wound healing grade alginate required
greater units of alginate lyase to achieve degradation within the 12 day period. In contrast, medical
grade alginate degraded over a longer period of time and the diameter of the microbeads increased.
Despite both types of alginate having similar ratios of M units to G units, differences in purity as
well as alginate chain length may have played a role in the degradation rate [70]. The presence of
polyphenols in the wound healing alginate does not appear to be responsible, however, since
polyphenols have been shown to reduce the activity of alginate lyase in aerobic degradation [72,
73].
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Degradation of alginate microbeads via alginate lyase occurs by two mechanisms;
enzymatic cleavage and ion exchange. In the first few days, degradation is primarily due to
enzymic cleavage of the glycosidic bonds between the M units. In our system, this was evidenced
by the production of uronate products in the first four days of incubation. Once the glycosidic
bonds are broken, the Ca++ ion crosslinks become more susceptible to ion exchange. The alginate
structure disintegrates as a result of the out flux of Ca++ ions, which are replaced by monovalent
ions resulting in decreased cross-linking density and, thus, a weakened hydrogel structure
associated with an increase in pore size [74]. This two part mechanism likely contributed to the
changes observed in microbead diameter over the 12 day period. The reduced crosslinking density
coupled with the inward diffusion of other molecules resulted in the swelling observed in medical
grade alginate microbeads. It is possible that a similar process takes place with microbeads
produced using wound healing grade alginate, but it is more likely that the rapid cleavage of
glycosidic bonds caused erosion of the surface of the microbead resulting in a decreased diameter.
The controlled release of cells was illustrated with various cell types demonstrating the
versatility of the delivery system. For all three cell types, 1.4 U/g alginate lyase released most of
the cells on day 2, while 0.09 U/g caused a gradual release of cells up to day 12. Alginate
degradation in the absence of cells occurred more slowly. The ratio of alginate lyase to alginate
was adjusted to account for the difference in degradation rates in the presence of cells. This
difference is due to the reduced alginate content in each microbead. Mammalian cells do not
possess alginate lyase, ruling out the possibility that native cellular enzymes contributed to
microbead degradation.

Additionally, the cells begin to leave the microbeads before total

degradation occurs as observed with 0.35 U/g group where the majority of the cells were released
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on day 4, but without cells the total degradation did not occur in 12 days. Also in the presence of
the cells and as time increases, alginate has been shown to decrease in gel strength [74].
The viability of cells post-injection is critical to the success of injectable cell-based
therapies. Injection of stem cells is known to result in low viability ranging from 1% to 32%
because of the harsh environment at the injury site and the mechanical disruption of the cell
membrane by extensional flow during ejection from the needle [47]. Delivering cells in crosslinked
alginate by injection has been shown to improve cell viability because of its protective effects
during ejection via “plug flow”. This plug flow occurs when the hydrogel near the wall acts as a
lubricant, protecting the rest of the hydrogel by allowing it to stay intact and move through the
needle [47].
Once the cells are injected, the alginate can provide further protection while retaining them
at the injury site. Our results indicate that cells encapsulated in the microbead formulations tested
in this study are viable in the microbead environment, indicating favorable mass transfer of
nutrients. The small increase in the number of viable cells noted in microbeads produced without
enzyme may have been due to proliferation or to retention of secreted factors within the microbead
[48] or to limited apoptosis. Moreover, inclusion of alginate lyase in the alginate did not have a
negative impact on viability of ASCs released from the microbeads. Indeed, viability of cells
released from microbeads containing alginate lyase was greater than from microbeads without
enzyme. This suggests that the weakened structure of the alginate microbead due to cleavage of
glycosidic bonds may have improved nutrient transfer.
Importantly, ASCs released from the microbeads did not exhibit major differences from
cells that had never been microencapsulated, at least as a function of growth in osteogenic medium.
At the time of release, cellular alkaline phosphatase specific activity was comparable for all
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formulations of microbead. Released cells cultured in monolayer to confluence and then for 7
days in osteogenic medium had comparable alkaline phosphatase activity to ASCs that had never
been previously microencapsulated. Similarly, mRNA levels for the osteogenic transcription
factors Runx2 and Osx were not different compared to the monolayer cells, nor were mRNA levels
for Col1.
Our results also suggest that microencapsulation may enhance the osteogenic potential of
the ASCs with respect to their ability to produce paracrine factors that stimulate bone formation.
The released ASCs exhibited reduced DNA content and increased osteocalcin production
compared to the never-encapsulated ASCs after 7 days in OM. This was correlated with increased
levels of Bmp2 mRNA, suggesting that BMP2 might act as an autocrine/paracrine regulator of the
microencapsulated cells. Interestingly, expression of Bmp2 was accompanied by expression of its
inhibitors, Grem1 and Nog, but in a differential manner. The significance of this is not known at
this time, but other studies have shown that these proteins are regulated independently [75].
There was not complete convergence between mRNA levels at 8 hours post-treatment with
osteogenic medium and protein levels at 24 hours for a number of factors, including osteocalcin,
VEGF and FGF2, which may reflect normal cellular transcription and translational controls.
Interestingly, mRNA expression was more sensitive to differences in microbead formulation.
Cells encapsulated in alginate containing alginate lyase had greater expression of Bmp2, Grem1
and Fgf2 than cells that had been encapsulated in alginate without enzyme. Similarly, for some
mRNAs, having the experience of encapsulation caused greater expression than seen in ASCs that
had not been encapsulated, even though the same starting population of ASCs was used for these
experiments. Previous research has shown that glucocorticoids can decrease production of
angiogenic factors [56], suggesting that the dexamethasone present in osteogenic medium may
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have inhibited VEGF production by the cells. The fact that Vegf mRNA was not affected and that
the ASCs produced both Fgf2 mRNA and FGF2 protein argues against this, however.
It is important that the results gathered in vitro can be obtained in vivo to ensure that the
delivery system is capable of working. Therefore alginate microbeads without cells (0 U/g and
1.75 U/g) were placed subcutaneously to determine if degradation would occur and whether or not
the by-products of alginate lyase mediated degradation would elicit an inflammatory response. At
the end of two weeks the alginate microbeads incorporating alginate lyase were not present thus
showing that degradation took place while in the control group alginate microbeads were present
in all the samples. The histological analysis of the skin shows that there was no leukocyte
infiltration thus indicating no inflammatory response.
5.5. Conclusions
In conclusion, we have developed a degradable and injectable delivery system for stem
cells where the time of cell release can be modulated for specific applications. The controlled
degradation was achieved through the incorporation of alginate lyase into alginate microbeads.
This system has shown that it can be used with multiple cell types. The cells released from the
microbeads remained viable and maintained their ASC phenotype with respect to growth in
osteogenic medium. Importantly, the results also show that mRNA expression of released cells is
more sensitive to microbead formulation than protein production at the time points assayed. The
released cells express higher levels of mRNAs associated with paracrine regulation of
osteogenesis, suggesting they may positively impact bone formation in vivo. These
microencapsulated cells can be directly injected to the site of injury. Therefore, in cases where
surgery is usually required for fractures or non-unions, this stem cell delivery method can be used,
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allowing controlled release of cells and the production of factors thus enhancing tissue
regeneration.
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CHAPTER 6

Microencapsulated Rabbit ASCs supported Chondrogenesis in a Rabbit
Auricular Defect Model

Summary
Cell-based tissue engineering can promote cartilage tissue regeneration, but cell retention
in the implant site post-delivery is problematic. Alginate microbeads containing adipose stem cells
(ASCs) pretreated with chondrogenic media (CM) have been used successfully to regenerate
hyaline cartilage in critical size defects in rat xyphoid suggesting that they may be used to treat
defects in elastic cartilages like the ear. To test this, we used microbeads containing rabbit (rb)
ASCs in critical size defects in New Zealand White rabbit ear cartilage. Low viscosity, high
mannuronate medical grade alginate microbeads were generated using a high electrostatic potential
and a calcium crosslinking solution containing glucose. rbASCs were isolated from inguinal fat
pads of male New Zealand White rabbits and their multipotency validated. Microencapsulated
rbASCs cultured in chondrogenic media expressed mRNAs for aggrecan, type II collagen, and
type X collagen. Microbeads were implanted in 3mm defects created using a trephine in the midcartilage located in the ear of each 6 skeletally mature male rabbits (empty defect; microbeads
without cells; microbeads with cells; degradable microbeads with cells; and autograft). At 12
weeks post-implantation, cartilage regeneration was assessed by microCT and histology.
Microencapsulated rbASCs induced cartilage regeneration as well as formation of bone-like tissue
in the defects. Elastin, the hallmark of auricular cartilage, was not evident in the neocartilage. This
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delivery system offers the potential for regeneration of auricular cartilage but factors that induce
elastin and consideration of the vascularity of the treatment site must be considered.
6.1 Introduction
Cartilage replacement is one of the top five cosmetic surgical procedures performed each
year involving the ear and nose, as well as congenital birth defects in the United States [1].
Cartilage is difficult to regenerate due to its avascular nature making any repair or replacement of
this tissue slow or challenging to achieve. Therapies that repair elastic cartilage include
implantation of cell-laden scaffolds [76] and reshaping cartilage harvested from another site within
the body [1], but these approaches frequently do not lead to complete cartilage regeneration.
Moreover, donor site morbidity and lack of available tissue in the case of grafting, and cell
migration compounded with low cell viability in the case of tissue engineering techniques, limit
success [77, 78].
A more focused approach using a cell-based therapy that would maintain the viability,
retention, and phenotype of the cells once implanted should improve tissue regeneration. We
previously showed that alginate microbeads containing adipose stem cells (ASCs) pretreated with
chondrogenic media could be used successfully to regenerate hyaline cartilage in critical size
defects in the rat xyphoid [48]. This suggested that a similar approach could be used to treat critical
size defects in elastic cartilages like the ear.
Alginate is found in seaweed and is a block copolymer that contains blocks of guluronic
acid, mannuronic acid, or alternating guluronic-mannuronic acid residues [24]. This biopolymer
instantaneously forms a hydrogel once it comes in contact with calcium forming an ionic bond
between guluronic acid and Ca++. The material is currently used in biomedical engineering for
drug delivery, regenerative medicine, and wound healing [79, 80]. Using a microencapsulator to
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apply an electrostatic charge in combination with a calcium crosslinking solution containing
glucose, cells can be incorporated into alginate microbeads that are ≤200 µm in diameter, with cell
viability greater than 85% in vitro after 2 weeks [81]. Moreover, cells within the beads are viable
after 3 months in vivo [4]. The hydrogel system provides small diffusion distances allowing the
exchange of nutrients, wastes and secreted factors.
Despite the biocompatibility of alginate, the polymer does not degrade in vivo. Alginate
may persist up to six months at the delivery site, thus preventing the release of cells and secreted
factors [6]. Recently, we showed that controlled cell release from alginate microbeads can be
achieved by incorporating alginate lyase [34]. This enzyme acts through a β-elimination
mechanism to cleave the glycosidic bonds between mannuronate residues [26]. Controlling the
rate of release by varying the rate of microbead degradation allows the encapsulated cells to aid
tissue regeneration in addition to the secretion of factors, which affects cell signaling and induces
endogenous progenitor recruitment to facilitate tissue repair [81].
In this study, we developed an auricular cartilage critical size defect model in adult male
New Zealand White rabbits and used it to examine the utility of the microbead technology for
regenerating elastic cartilage. We hypothesized that the controlled release of rbASCs and secreted
factors will lead to induction of cartilage in an auricular critical size defect.

6.2. Methods
6.2.1 Adipose Derived Stem Cells
rbASCs were isolated from New Zealand White rabbits rats (n = 2) [2, 36], under an
Institutional Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute
of Technology. Briefly, the inguinal fat pad was removed and transferred to a container with
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Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supplemented with 3% sterile-filtered
L-glutamine-penicillin-streptomycin (P/S). The tissue was washed three times with Hank’s
balanced salt solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–
ethylenediaminetetraacetic acid (EDTA) for 30 minutes on a rocker at 37°C. Following
trypsinization, the supernatant was discarded. Adipose tissue was cut into small pieces and
incubated in a digestive cocktail containing collagenase type I (365 units/mL) (Sigma Aldrich) and
dispase (3 units/mL) (Gibco) for four hours. After incubation, the oily upper layer was removed
and the digest was quenched with an equal amount of MSCGM. The cells were separated, plated
in T-175 flasks at 5,000 cells/cm2 and cultured in MSCGM at 37 °C and 5% CO2. For the next two
days the monolayers were washed with Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen)
and fed with MSCGM every 24 hours. Thereafter media were changed every 48 hours and cells
were cultured to confluence. First passaged cells were used for the phenotype studies.
6.2.2 Phenotype of rbASCs
To investigate the multipotency of rbASCs, cells were plated at 5000 cells/cm2 and cultured
in MSCGM until confluent. rbASCs were treated with MSCGM, osteogenic differentiation
medium (OM, Lonza), chondrogenic differentiation medium (CM) and adipogenic differentiation
medium (AM, Lonza) for 18 days. The CM was made with high glucose DMEM (4.5 g/L glucose),
110 mg/L sodium pyruvate (Sigma Aldrich), 50 µg/mL ascorbic acid 2-phosphate (Sigma
Aldrich), 10 nм dexamethasone (Sigma Aldrich), 1% ITS+ (Sigma Aldrich), 40 µg/mL proline
(Sigma Aldrich), 100 ng/mL of the recombinant human bone morphogenetic protein 6 (PeproTech,
Rocky Hill, NJ), and 10 ng/mL recombinant human transforming growth factor beta-1 (R&D
Systems, Minneapolis, MN).
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6.2.2.1 RNA Extraction and Real Time PCR
RNA was extracted 8 hours after the last medium change using TRIzol ® [Invitrogen] and
quantified with the Nanodrop Spectrophotometer (Thermo Scientific, Waltham, MA). Samples
were then converted into cDNA by the reverse transcription of 1 µg RNA with random primers
(Applied Biosystems, Warrington, UK) and Multiscribe Reverse Transcriptase (Applied
Biosystems). The cDNA was analyzed for mRNA levels by real-time PCR using the StepOne Plus
PCR System (Applied Biosystems). mRNA levels for the following proteins were measured;
collagen type II (COL2), collagen type X (COL10), runt-related transcription factor 2 (RUNX2),
peroxisome proliferator-activated receptor gamma (PPAR-γ), aggrecan (ACAN), leptin receptor
(LEPR), and osteocalcin (bone gamma-carboxyglutamate protein, BGLAP). All primers (Table
6.1) were designed using the NCBI program and then synthesized by Integrated DNA
Technologies (IDT). The mRNA levels were quantified relative to a standard curve of known
concentration, and results were normalized to the transcript levels of the housekeeping gene,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
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Table 6.1. Primer sequences used for the analysis of mRNA levels
Gene
ACAN
COL2
COL10
GAPDH
LEPR
OCN
PPAR-γ
RUNX2

Forward Primer
Reverse Primer
GGA GCA GGA GTT TGT CAA CAA CAA CCA GTT CTC AAA TTG TAG
C
GGG GTG T
AGA AGA ACT GGT GGA GCA GCA AGA AGG CTG CTG TCT CCA TAG
G
CTG AAG
ACC TTG TTC TCC TCT CAC
GTT CAT GGA GTG TTC TAC GCT GAG
TGG
TGCTGTCGAGACTTTATTGA
CAGTTTCCATCCCAGACCCC
TGGT
GTTGGCCTTAAGGTCCATCTTTTATATG GCTGCTGGCACAGGCACAT
TTCTGCCT
GAC
CTCCCTCTTGGACACGAAG
CCTCACTCTTGTCGCCCTGCTG
GCTGAG
CAG CAT CTC TGC TCC ACA CTA TGA AGG TTC CAC TTT GAT TGC
A
ACT TTG A
ACTCTGGCTTTGGGAAGAG
CATGTCCCTCGGTATGTCCG
C

6.2.2.2 Histological Stains
Multipotency of rbASCs was also demonstrated via the use of histological stains of
cultured cells. P1 rbASCs were plated at 5000 cells/cm2 in 6-well plates. At confluence, cells were
treated with MSCGM, OM, and AM for 14 days. Cells differentiated along the osteogenic lineages
were stained with alkaline phosphatase and Alizarin Red. Cells differentiated along the adipogenic
lineage were stained with Oil Red-O. Cell differentiation along the chondrogenic lineage was
performed using pellet culture. Briefly, 150,000 cells were spun at 5000 RPM for 10 minutes in a
15 mL conical tube. Pellets were cultured for 14 days in CM. The pellet was embedded in paraffin
and sections were stained with Alcian Blue. All stains were compared to an equivalent sample
cultured in MSCGM as the control. In addition, sections were examined for the presence of elastin
as described below for histologic analysis of regenerated ear cartilage.
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6.2.3 Microencapsulated Cells
Low viscosity medical grade alginate (50% mannuronate units) (PRONOVA™ UP LVM,
ultrapure sodium alginates, FMC BioPolymer) was dissolved in 0.9% (w/v) saline (Ricca
Chemical) at a concentration of 40 mg/ml. Microbeads were created using a Nisco Encapsulator
VAR V1 LIN-0043 (Nisco Engineering AG) at a 5 ml/hr flow rate, nozzle with an inner diameter
of 0.12 mm, an electrostatic potential of 6 kV and a calcium crosslinking solution. The crosslinking
solution contained 75 mM CaCl2, 90 mM glucose with 10 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid at pH 7.3 (Sigma Aldrich) (HEPES-buffered) [70]. Alginate
microbeads were allowed to crosslink for an additional 10 minutes, washed with 0.9% (w/v) saline
(Ricca Chemical) to remove the excess Ca++, and suspended in saline supplemented with calcium
chloride (1.8 mM Ca++) at 370C.
Degradable alginate microbeads were made by incorporating alginate lyase in the
microbeads following the methods described in Leslie et al. [34]. Briefly, equal volumes of 4%
alginate and a known concentration of alginate lyase solution combined in 0.9% (w/v) saline. At
confluence, rbASCs were treated with CM for 7 days. The cells were released from the culture
plate by trypsinization and collected by centrifugation after rinsing the cell pellet with MSCGM.
The cells were then suspended in the alginate lyase/alginate mixture at a concentration of 10 x 106
cells/ml. Non-degradable microbeads incorporating rbASCs were made similarly with the
exception of adding alginate lyase. Alginate microbeads were then formed as previously described
and suspended in MSCGM for 24 h.
6.2.3 Phenotype of Microencapsulated rbASCs
To investigate whether or not microencapsulation affects the chondrogenic effects of CM,
microencapsulated rbASCs (10 x 106 cells/ml) were treated with MSCGM for 3 days then CM or
MSCGM for 7 days.
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6.2.3.1 Soluble Factor Quantification
Enzyme-linked immunosorbent assays (ELISA) were used to measure the levels of
vascular endothelial growth factor A (VEGF), transforming growth factor beta 2 (TGFβ2), bone
morphogenetic protein 2 (BMP2) and transforming growth factor beta 3 (TGFβ3) (R&D Systems,
Minneapolis, MN) in the conditioned medium and retained in the microbeads. To measure growth
factor retention within microbeads, beads were collected, uncrosslinked in 82.5mM sodium citrate,
lyophilized and resuspended and digested in alginate lyase (1U/ml) (Sigma Aldrich) for one hour
and measured with ELISAs. All ELISAs were normalized by the DNA content of the cells.
6.2.3.2 DNA Quantification
The digested microbeads were used to determine the DNA content (Quant-iT™
Picogreen® ds DNA Reagent, Invitrogen) of the microencapsulated cells.
6.2.3.2 mRNA Levels
ACAN, COL2, and COL10 mRNA levels were measured as previously described in
section 6.2.2.1 and normalized by GAPDH.
6.2.4 Cartilage Ear Defect In Vivo
6.2.4.1 Rabbit Auricular Cartilage Defect Surgery
All surgical procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the Georgia Institute of Technology. Male New Zealand white rabbits (2
– 3 kg, n = 6) were induced with a ketamine and xylazine intramuscular injection; anesthesia was
maintained with inhaled isofluorane gas. Each animal was placed prone on the operating table and
a 6 cm incision was made extending from the tragus to the mid-helix. A flap was created both
anteriorly and posteriorly by elevating the perichondrium from the auricular cartilage. To create a
full thickness defect, a dermal biopsy punch (Miltex Inc., Plainsboro, New Jersey) was used. In
each ear, defects were made by placing a surgical stainless steel ruler in the posterior flap for
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support and a dermal biopsy punch was used to create a full thickness cartilage defect. The skin
incision was closed using 5-0 PDS (polydiaxanone) suture (Ethicon, Somerville, NJ) using a
simple running technique.
6.2.4.2 Determining Critical Cartilage defect size
Prior to assessing the ability of microencapsulated rbASCs (n = 3) to initiate cartilage
regeneration, a rabbit auricular cartilage critical size defect model was developed. Cylindrical full
thickness defects were created using 1, 3 and 4 mm dermal biopsy punches (Miltex Inc). The
defects were separated by 1 mm. In one ear of each animal, the autograft for the respective defect
size was used to fill the defect to compare healing. After six weeks, the defects were examined for
the degree of healing using equilibrium partitioning of an ionic contrast agent microCT (EPICmicroCT) (Scanco Medical) [82, 83].
6.2.4.3 Implantation of Microencapsulated rbASCs
The protocol used to assess the ability of the microencapsulated rbASCs to regenerate
auricular cartilage is shown in Figure 6.1. rbASCs were cultured in CM for 7 days and
microencapsulated in low viscosity, high mannuronate alginate microbeads as described above.
Five 3 mm defects were made in each ear. Four defects were separated by 1.5 cm and a fifth defect
(autograft) was created medially 1.25 cm away from the most superior defect. A 4 mm x 4 mm
piece of SepraFilm ® (Genzyme Corporation, MA) was placed posteriorly to each defect. Each
defect was filled with the respective treatment as outlined in the experimental schematic (Fig. 6.1).
The five treatments in each ear included empty defect, non-degradable alginate microbeads
containing rbASCs, non-degradable alginate microbeads, degradable alginate microbeads
containing rbASCs, and an autograft. Each defect with a microbead treatment received 100 µl of
microbeads (approximately 2500 microbeads). Each defect was sealed with a 4 mm x 4 mm piece
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of SepraFilm. After 12 weeks the posterior skin was removed and the defects were recovered. A
total of 6 rabbits were used with each ear receiving the procedure, resulting in a total of 12 samples
per group.

Figure 6.1. Schematic outlining the experimental method. rbASCs that were previously treated
with chondrogenic media for 7 days were microencapsulated and delivered to the appropriated
defect site: 1. empty, 2. non-degradable microbeads incorporating rbASCs, 3. non-degradable
microbeads without rbASCs, 4. degradable microbeads incorporating rbASCs, and 5. autograft.
After 12 weeks the defects were harvested and analyzed via microCT and histology.

6.2.4.4 Epic MicroCT to Assess Neocartilage Formation
To assess the degree of healing in each defect, contrast-enhanced microCT analysis
technique based on equilibrium partitioning of an ionic contrast agent (EPIC-microCT) was used
[82]. Using this method we quantified the tissue volume and density within each defect. Once the
defects were harvested they were placed in 10% neutral buffered formalin (VWR) for 24 h and
transferred to 40% Hexabrix and 60% phosphate buffered saline incubated for 12 h at 370C. All
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samples were scanned in air using a µCT 40 (Scanco Medical) at 45 kVp, 200 µA, 600 ms
integration time, and a voxel size of 35 µm. Images were processed using the accompanying
Scanco Medical software. A constant volume of interest representing the absolute volume centered
at the defect cavity was used for the analysis of each sample. The diameter of the volume of interest
was 3 mm by 3 mm. To observe three-dimensional distribution of sulfated glycosaminoglycan
(GAG) in the tissue, color images were based on the X-ray attenuation. Low X-ray attenuation
(green and blue) corresponded to regions of high proteoglycan concentration and high X-ray
attenuation (red and yellow) indicated regions of low proteoglycan concentration.
6.2.4.5 Histology
After 48 h of fixation in neutral buffered formalin, samples were dehydrated in a series of
95% and 100% ethanol and xylene washes. Samples were embedded in paraffin, and cut into 8 μm
thick sections (Shandon Finesse 325, Thermo Scientific). The sections were stained with
haematoxylin and eosin, safranin O, or Masson’s trichrome and then imaged with a Zeiss
Observer.Z1 axio microscope (Leica Microsystems, Bannockburn, IL).
In addition, we examined the tissues for the presence of elastin using ab150667 Modified
Verhoeff’s stain kit (Abcam, Cambridge, UK). Deparaffinized, hydrated sections were incubated
for 15 minutes in elastic stain containing haematoxylin solution, ferric chloride, and Lugol’s iodine
solution. After rinsing in tap water, the sections were dipped 20 times in a differentiating solution,
rinsed and incubated in sodium thiosulfate solution for 1 minute. After rinsing in tap water, they
were stained using van Gieson’s solution for 2-5 minutes, rinsed twice in 95% alcohol, dehydrated
in absolute alcohol, cleared and mounted. This method stains elastic fibers black to blue/black,
nuclei are blue to black, collagen is red, and muscle and other tissues are yellow.
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6.2.4.6 Histomorphometric Analysis
To analyze the ability of the microencapsulated rbASCs to induce cartilage regeneration,
the area of the new cartilage and the defect width were measured using IMAGE J software (NIH,
Bethesda, MD). The area of new cartilage was identified by a color change in the H&E staining mature cartilage (dark purple) to newly formed cartilage (light purple). Percent healing was
defined as the summation of all cartilage or bone-like tissue within the borders of the defect divided
by the width of the original defect.
6.2.5 Statistical Analysis
Data are presented as the mean with standard error. Statistically significant differences
between groups were determined by one-way ANOVA followed by Bonferroni’s modification of
Student’s t-test. P values ≤ 0.05 were considered significant.

6.3. Results
6.3.1 Multipotentiality of rbASCs
Gene expression was sensitive to the culture media in which the rbASCs were cultured.
rbASCs treated with CM for 18 days had higher mRNAs for COL2, ACAN, and COL10 than cells
cultured in GM (Figs. 6.2A,B,C), but did not produce elastin (data not shown). Similarly, rbASCs
in OM had significantly higher mRNAs for RUNX2 and BGLAP compared to rbASCs treated
with GM for the same period (Figs. 6.2D and 6.2E). Cells cultured in AM had significantly higher
mRNAs for LEPR and similar levels of mRNA for PPAR-γ compared to those treated with GM
(Figs. 6.2F and 6.2G).
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Gene expression was confirmed by histologic staining of the cultures. rbASCs cultured as
a pellet in CM for two weeks showed a higher presence of proteoglycans with Alcian Blue staining
than cells in GM (Fig. 6.2H). rbASCs cultured in OM for two weeks had greater calcium deposition
and alkaline phosphatase staining than cells in GM (Fig. 6.2I), while rbASCs treated with AM had
a greater presence of oil droplets with Oil Red O staining (Fig. 6.2J).

Figure 6.2: Multipotency of rbASCs. mRNA levels for COL2, ACAN, COL10, RUNX2, BGLAP,
PPAR-γ, and LEPR (A-G); Alcian Blue staining of a 3D culture of rbASCs cultured in MSCGM
and CM (H); alkaline phosphatase (ALP) and Alizarin Red staining of rbASCs cultures in
MSCGM or OM (I); and Oil Red-O staining of monolayer cultures cultured in MSCGM or AM
(J). Magnification 10x.
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6.3.2 Chondrogenic Phenotype of Microencapsulated rbASCs
Microencapsulated rbASCs exhibited chondrogenic differentiation when cultured in CM.
mRNAs for ACAN, COL2, and COL10 were increased compared to microencapsulated cells
cultured in GM (Figs. 6.3A,B,C). Levels of TGFβ2 and TGFβ3 in the conditioned media and
retained within alginate microbeads were significantly higher than in GM cultures (Figs.
6.3D,E,F,G). BMP2 levels were comparable when microbeads were cultured in CM or GM
(Figs. 6.3H,I). VEGF levels in the conditioned media of microbeads cultured in CM were
significantly lower compared to GM cultures, but there was no difference in the amount of
VEGF retained within the microbeads (Figs. 6.3J, K).

Figure 6.3. Phenotype of rbASCs after microencapsulation. mRNA levels for ACAN, COL2, and
COL10 (A-C); and production of TGFβ2, TGFβ3, BMP2, and VEGF by microencapsulated
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rbASCs treated with MSCGM and CM for 7 days. Data were analyzed using one-way ANOVA
followed by Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. MSCGM.
6.3.3 Determination of Rabbit Auricular Cartilage Critical Size Defect
After six weeks, empty defects of 1 mm, 3 mm, and 4 mm in diameter did not regenerate,
as shown in the histological sections (Figs. 6.4A,B,C). A similar result was observed in the
microCT images of 1 mm and 3 mm diameter empty defects (Figs. 6.4A,B). Neocartilage was not
observed at the margins of the autograft and defect suggesting the autograft did not integrate with
the adjacent cartilage tissue (Figs. 6.4D,E,F). MicroCT confirmed the presence of cartilage in the
autografted defect sites. Based on these results, all subsequent surgeries were performed using a
3 mm defect.

Figure 6.4. Critical size defect in auricular cartilage. H&E staining and microCT images of empty
defects (A, B, C) and the corresponding autografts of 1, 3, and 4 mm in diameter (D,E,F).
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6.3.4 EPIC-microCT Analysis
Analysis of the defect sites at 12 weeks post-surgery showed that sites receiving autograft
had a significantly greater total volume of tissue compared to all other groups (Fig. 6.5A). The
average attenuation of the defect site was significantly greater when defects were treated with
degradable microbeads containing rbASCs compared to all other groups (Fig. 6.5B). Empty
microbeads and autograft had similar levels of attenuation, and were significantly higher than
empty defects. Representative images of the defect locations and attenuation maps are shown in
Figures 6.5C and 6.5D respectively.

Figure 6.5. MicroCT analysis of tissue in defects at 12 weeks post-surgery: tissue volume within
the defect site (A), average attenuation of the defect site (B), 3D images of ear with defect location
(C); and attenuation map of defects (D). Data were analyzed using one-way ANOVA followed by
Bonferroni’s modification of Student’s t-test. * p < 0.05 vs. empty defect, $ vs. µBs with rbASCs,
^ vs. degradable µBs with rbASCs.
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6.3.5 Histomorphometric Analysis of Cartilage Ear Defects
Histological analysis showed the infiltration of fibrous tissue after 12 weeks in empty
defects (Fig. 6.6A). In contrast, autografts had the appearance of normal auricular cartilage but as
noted above, it was not integrated with the margins of the defect (Fig. 6.6B). Autografts did not
lead to either partial or complete healing. While the autograft maintained the structural properties
of cartilage, there was no reintegration of the autograft with the defect tissue. Empty microbeads
were still observed in the defect site surrounded by fibrous connective tissue (Figs. 6.6C,D). Nondegradable alginate microbeads incorporating rbASCs initiated cartilage regeneration, and in one
case resulted in complete regeneration of the cartilage within the defect (Fig. 6.6E). Large areas of
newly formed cartilage were observed in these samples.

Figure 6.6. Defects after 12 weeks. H&E staining of: A – empty defect, B - autograft, C - nondegradable microbeads without cells, and D - magnified view of microbeads in C. E - H - Defects
incorporating non-degradable microbeads containing rbASCs. Defects treated with nondegradable microbeads containing rbASCs exhibited: newly generated cartilage, cartilage
interwoven with calcified tissue and immature bone-like tissue. Sections of one defect stained with
H&E (F), Safranin O (G), and Masson’s trichrome (H). Black arrows point to the newly formed
cartilage and yellow arrows point to the original cartilage.
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Degradable alginate microbeads containing rbASCs produced a different tissue response.
Bone-like tissue adjacent to the defect margins was evident in H&E stained sections of the defect
sites (Fig. 6.7F). This region also positively stained with safranin O, indicating cartilage was
present as well (Fig. 6.7G). Masson’s trichrome staining of these samples confirmed that immature
bone-like tissue was present (Fig. 6.7H).

Figure 6.7. Defects filled with degradable microbeads incorporating rbASCs. Histological stains
of different regions of the same defect: H&E (A), Safranin O (B), Masson’s trichrome (C). Inset
on left shows a magnified version of newly formed bone (Magnification 40x). Green arrows point
to newly formed bone/calcified tissues. Radiographic image of defect with calcified tissue and the
corresponding H&E staining (D).

There was no evidence of elastin in the neocartilage formed within the defect sites (Fig.
6.8). Normal chondrocytes in the auricular cartilage adjacent to the defect exhibited the
characteristic pericellular staining indicative of elastic fibers (Fig. 6.8A). However, chondrocytes
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in the neocartilage in the defect sites showed mainly collagen in the extracellular matrix (Figs.
6.8B,C,D).

Figure 6.8. Normal chondrocytes have pericellular elastic fibers (A) while cells in the sites
implanted with nondegradable microbeads containing rbASCs are surrounded mainly by collagen
(B-D). Staining with Modified Verhoeff’s elastic stain; images taken at 40x magnification. Elastic
fibers are stained black to blue/black, nuclei stained blue to black, collagen stained red, and any
muscle and other tissue stained yellow.

Histomorphometry demonstrated that the defects that received non-degradable alginate
microbeads with rbASCs had the greatest area of new cartilage (Fig. 6.9A, Fig. 6.6E). In contrast,
the empty defects had significantly less cartilage than all other groups (Fig. 6.9A). New immature
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bone-like tissue was also evident in all defects (Fig. 6.9B, Fig. 6.7C), but the area of new bone was
small and to a comparable extent in all defect sites. This tissue was observed in microCTs of the
tissue (Fig. 6.7D), indicating that it was mineralized.

Figure 6.9. Histomorphometric analysis of the area of new cartilage (A); area of immature bonelike tissue (B); percent healing with new cartilage (C); and percent healing with immature bonelike tissue (D). Data were analyzed using one-way ANOVA followed by Bonferroni’s
modification of Student’s t-test. * p < 0.05 vs. empty defect, $ vs. µBs with rbASCs, ^ vs.
degradable µBs with rbASCs.

Histology showed that neocartilage and bone like tissue were present both inside and
outside the defect region. When examining only the cartilage and bone-like tissue within the
defect, percent healing of new cartilage for both degradable and non-degradable microbeads with
rbASCs were increased compared to other groups, but not significantly (Fig. 6.9C). The percent
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healing of immature bone-like tissue found in all defects was comparable regardless of treatment
(Fig. 6.9D).
There was considerable variation in tissue response among animals in the same treatment
group (Table 6.2). Empty defects only exhibited cartilage in 1 of 6 rabbit ears but immature bone
like tissue was present in 4 of the 6. One of these had both cartilage and bone in the defect tissue.
When defects were treated with non-degradable microbeads containing rbASCs, 7 of 11 rabbit ears
had cartilage and 7 of 11 had immature bone. All rabbit ears had either cartilage or bone, but only
3 had both cartilage and bone. Defects treated with microbeads that did not contain cells also had
cartilage (4/10) and bone like tissue (6/10). Seven of the rabbit ears had either cartilage or bone
but only 3 had both types of tissue within the defect site. In sites treated with degradable
microbeads containing rbASCs, 4 of 8 rabbit ears had cartilage and 6 of 8 rabbit ears had bone.
Seven of the 8 rabbit ears had either cartilage or bone but only 4 had both. In defects treated with
autograft, 4 of 11 animals had neocartilage, 7 of 11 had bone-like tissue; nine of the rabbit ears
had either neocartilage or bone but only 2 had both tissues in the defect site.

Table 6.2. Induction of cartilage and/or immature bone by microencapsulated rbASCs. Data are
the number of samples with new tissue in the defect site v. the number of total sites in a given
group.

Defect

Cartilage

Bone-like
Tissue

Empty
uBs with ASCs
uBs without ASCs
Deg. uBs with ASCs
Autograft

1/6
7/11
4/10
4/8
4/11

4/6
7/11
6/10
6/8
7/11
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Cartilage or
Cartilage and BoneBone-like
like Tissue
Tissue
4/6
1/6
11/11
3/11
7/10
3/10
7/8
4/8
9/11
2/11

There was no evidence of inflammation in any of the treatment sites. Alginate lyase
enzyme and the byproducts of alginate lyase mediated degradation did not lead to the infiltration
of leukocytes. Similarly, defects that received only alginate microbeads with and without rbASCs
did not exhibit an inflammatory response after 12 weeks.

6.4. Discussion
The therapy presented in this work packaged ASCs into injectable alginate microbeads that
are 200 µm in diameter and tested their ability to support cartilage regeneration in critical size
auricular cartilage defects. The results indicate that neocartilage formation can be achieved but
the chondrogenic regimen used to pretreat the ASCs led to a phenotype more typical of
commitment to an osteochondral lineage than to an elastic cartilage lineage. Moreover,
characteristics of the rabbit ear model, particularly the vasculature in the overlying skin, may have
contributed to the formation of immature bone in the regenerated tissues.
rbASCs have been used in tissue regeneration models for bone, cartilage, and cornea, but
it has not been explicitly demonstrated that these stem cells are multipotent [84-86]. Our results
show that, like rat and human ASCs [2, 87], rbASCs are multipotent and are able to differentiate
along osteogenic, adipogenic, and chondrogenic lineages. Expression of mRNAs for phenotypic
marker proteins was significantly higher in the respective differentiation media compared to
control cultures. Additionally, all histological stains confirmed that rbASCs are able to
differentiate along all three lineages.
Microencapsulated rbASCs maintained their chondrocyte phenotype after encapsulation.
They expressed mRNAs for aggrecan (ACAN) and type 2 collagen (COL2), both of which are
extracellular matrix proteins found in hyaline cartilage. They also expressed mRNAs for type X
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collagen, which is typically found in hypertrophic growth plate chondrocytes, suggesting that these
cells primed the regenerating tissue to support endochondral bone formation.

The

microencapsulated rbASCs secreted TGFβ2 and TGFβ3, both of which are associated with
chondrogenesis [88], indicating that their presence in the defect sites may have contributed to
neocartilage formation. The CM-treated rbASCs also secreted BMP2, an osteogenic factor, but
not to a greater extent than the GM treated cells. Moreover, treatment with CM lead to a marked
reduction in VEGF secretion. Taken together, these data suggest a complex cocktail of factors
was generated by CM treatment that caused an endochondral lineage commitment while at the
same time, reducing the vasculogenesis in the repair tissue generally associated with ossification.
We selected the rabbit ear as a model to test the effectiveness of the microbeads in
regenerating cartilage based on published reports using this method [89, 90].We were able to
define criteria for a critical size defect in the rabbit ear cartilage. Based on our findings, the 3 mm
defect was chosen due to its size for microbead implantation and ease of manipulation during
surgery.
However, our results using multiple end points indicate that there are limitations that must
be taken into consideration in future study designs. It should be noted that although autografts
maintained the structural properties of cartilage, there was no reintegration of the autograft with
the cartilage bed. In addition immature bone like tissue was present in all of the treatment groups.
This was unexpected, given that the rbASCs were pretreated with CM and produced factors
associated with chondrogenesis. The CM-treated rbASCs did not produce elastin, the hallmark of
elastic ear cartilage, suggesting that they had not fully differentiated along an auricular
chondrocyte lineage prior to implantation. Our results indicate that factors present in the
surrounding tissue were insufficient to support auricular chondrocyte differentiation of the
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implanted microencapsulated cells, at least over the time frame of the study. Moreover, the tissue
overlaying the auricular cartilage is highly vascularized and bleeding during microbead placement
may negatively impact chondrogenesis. These results are consistent with other reports of bone
formation in auricular cartilage defects from tissue engineered constructs [91].
Even with these limitations, our results show that the formatting of the rbASCs contributed
to the degree of chondrogenesis that was observed in the defects. The greatest amount of
neocartilage was generated in sites implanted with non-degradable microbeads containing CMtreated rbASCs. These cells not only secreted higher levels of TGFβ2 and TGFβ3 than GM-treated
rbASCs, but they retained these factors within the microbead itself. Moreover, VEGF secretion
was markedly reduced. This suggests that secreted factors remained in a concentrated area within
the defect leading to the induction of new cartilage and suppression of vasculogenesis. The
neocartilage was present in small islands of tissue within the defect, and in one case, nearly
spanned the full width of the defect. Although we expected to see the microbeads remaining in the
tissue after 12 weeks, they were no longer present in most samples, possibly due to enzyme activity
from neighboring defects containing degradable microbeads.
Degradable microbeads containing rbASCs also supported neocartilage formation, but to a
lesser extent than the non-degradable beads containing rbASCs. However, production of bonelike tissue was highest in this group. Highly attenuated tissue on microCT corresponded to
immature bone-like tissue based on Masson’s trichrome stained sections [92]. One possibility is
that the CM-treated rbASCs released from these microbeads had a more hypertrophic chondrocyte
phenotype than those retained in a rounded hyaline cartilage cell shape within the non-degradable
microbeads, and as such supported endochondral ossification within the defect. The degradable
microbeads were designed to release cells approximately 4 to 6 days post-implantation [34]. In
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contrast, the retention of cells within the non-degradable microbeads may have allowed the defect
site to have more exposure to the chondrogenic factors, thereby affecting chondrogenic
differentiation of surrounding cells.

6.5. Conclusions
Cell-based therapy will be beneficial to patients in need of cartilage regeneration for
craniomaxillofacial problems. Multipotent rbASCs formatted in alginate microbeads 200
micrometers in diameter can be delivered to auricular cartilage defects to stimulate
chondrogenesis. Our results using a rabbit auricular cartilage critical size defect model suggest
that it may be necessary to specifically induce rbASCs along an auricular cartilage cell lineage to
ensure elastic cartilage formation without new bone formation in a well vascularized site.
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CHAPTER 7

7.1 Discussion
Approximately 5-20% of fractures end in non-union due to the lack of growth factors and
stem cells to aid in regeneration and repair. In some cases, the defect gap is too large for the body
to heal on its own with bone [1]. Bone regeneration requires three important factors – cellular
components, growth and differentiating factors, and a scaffold matrix. Cellular components from
either exogenous cell sources or the local environment can give rise to new structural tissue.
Growth and differentiating factors can guide the development of cellular components. Both factors
can be provided exogenously using purified proteins or implanted cells secreting proteins and
endogenously from extracellular matrix deposits generated by resident tissue cells. Where there is
insufficient endogenous matrix to provide a substrate for cellular attachment, proliferation and
differentiation, it is also necessary to provide a scaffolding structure [16].
Three approaches have been applied to the tissue engineering of bone: (1) matrix-based
therapies, (2) factor-based therapies, and (3) cell-based therapies [16]. Matrix-based therapies use
an implant to provide structure and stability. This approach depends on the recruitment of
endogenous osteoprogenitors to repair the fracture. The implant’s surface aids in the regeneration
process by initiating MSC differentiation. Commonly used implants are constructed from titanium,
ceramics or hydroxyapatite. These implants tend to be porous and facilitate ingrowth of bone into
the pores however, the lack of their ability to induce bone formation limits their use significantly.
Although hydroxyapatite has been proven to be a good support for cell and matrix interactions in
bone formation, it requires many years before complete resorption occurs. In contrast, factor-based
therapies supply osteoinductive stimuli, which otherwise may not be present or insufficient.
Delivering growth factors has been successful in forming bone but is limited by the difficulty in
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translating results from rodent models to larger animals. In addition, the optimal method to deliver
and present these factors remains a challenge.
Cell-based therapies use the approach of delivering cells directly to the defect site. It is
challenging to determine which factors are needed in any injury site. The cell-based approach does
not rely on endogenous stem cells to produce new bone or growth factors; instead these factors are
produced by the cells that are delivered, thereby compensating for the growth factor deficiency
[16]. Cell-based therapies are particularly advantageous where the host tissue beds are
compromised and in cases where the patients suffer from severe trauma or diabetes or patients
with a limited number of osteoprogenitor cells because of age or osteoporosis.
Cell-based therapies may employ various cell types, including unfractionated bone
marrow, purified and cultured expanded MSCs, differentiated osteoblasts or chondrocytes, or cells
modified genetically to produce factors like rhBMP. Fresh bone marrow aspirates contain
osteogenic precursors, however a significant amount of bone marrow is required to acquire
sufficient cells thus making it an impractical source for large defects. An alternative source is
autologous MSCs that have been expanded ex vivo. MSCs that have been differentiated along the
osteogenic or chondrogenic lineage may also be used. Studies with pre-differentiated osteoblasts
combined with an implant have shown the production of significantly more bone. The last type of
cells are used for the delivery vehicle of genetic material coding for BMP2 [16].
The cell-based therapy developed in this thesis is a combination of applying the factorbased and cell-based approach. The factor-based approach is demonstrated by the growth factors
secreted by microencapsulated ASCs once they were cultured in MSCGM or differentiation media.
In our application, the matrix, alginate, was primarily used for localizing the cells rather than to
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provide an attachment substrate for the cells. However, others have modified the polymer to
provide attachment sites as well as bioactive ligands [93, 94].
Alginate microbeads are used as a mode of cell delivery in a number of fields and has great
potential for tissue regeneration. Our approach has differed from previous work by generating
microbeads that are less than 200 m in diameter, thereby ensuring adequate mass transport to
retain cell viability. Using this technology as my base, I have shown that these microencapsulated
cells are able to produce growth factors that will aid in tissue regeneration, thus displaying their
therapeutic potential. I have developed a method to control the release of cells from alginate
microbeads using alginate lyase. Furthermore when placed in vivo I have demonstrated that
degradable and non-degradable microbeads localize cells at the delivered site.
To investigate the ability of the microbead cell delivery system to facilitate tissue
regeneration, we used a rabbit ear cartilage critical size defect model using rbASCs. Delivery of
CM-treated rbASCs in alginate microbeads supported chondrogenesis, particularly when
nonresorbable microbeads were used. Immature bone-like tissue was present in most of the
treatment sites, but this was especially the case in sites treated with degradable microbeads. This
may have been due to higher VEGF levels secreted by rbASCs or the presence of many veins at
the site. Therefore to fully achieve elastic cartilage regeneration rbASCs may require a specific
culture regime that would prevent the cells from going along an endochondral ossification
pathway. In addition, another animal model could be used to assess the ability of
microencapsulated rbASCs to regenerated elastic cartilage.
Many human trials investigating the use of stem cells have not been completed or were
unable to assess the full potential of the use of stem cells partly due to the loss of cells after
delivery. Alginate microbeads are known to localize cells and therefore may enable the completion
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of human clinical studies assessing the effect of cell-based therapies on musculoskeletal defects.
The delivery system could be adapted for any other tissue once the appropriate cells are
microencapsulated. Microencapsulated cells are great for the production angiogenic factors
namely VEGF and FGF because of the minimally hypoxic microbead environment. Therefore,
microencapsulated stem cells would be effective in delivering angiogenic factors where
angiogenesis is needed. Angiogenesis is critical to wound healing, therefore microbeads could be
used in wounds that are difficult to heal. Microencapsulated ASCs in the muscle resulted in the
formation of adipose tissue and therefore could be useful in clinical settings where a void space is
remaining after a surgical procedure. Additional applications of the alginate microbead system
could be the delivery of any pharmaceutical products, even nanoparticles to aid in other treatments
since the degradation kinetics are controllable.
This delivery system enables the use of cell-based personalized medicine by
microencapsulating patient’s cells. This approach reduces the possibility for immune rejection. We
have also shown that only a few number of microbeads would be needed containing a small number
of cells which is particularly advantageous for patients with a small number of available stem cells.
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APPENDIX A

Osteoinductive Nature of Microencapsulated ASCs

Summary
Bone regeneration can be aided by bone graft substitutes due to their osteoconductive
properties. Some of the current bone graft substitutes are not osteoinductive. We have developed
a system of degradable and injectable alginate microbeads to deliver stem cells. ASCs secrete
osteogenic and angiogenic growth factors. ASCs treated with OM or OM-d have shown osteoblast
like properties. Therefore, we investigated the ability of microencapsulated ASCs derived from
different species to induce ectopic bone in different models. All ASCs were pretreated with
MSCGM or OM or OM-d. Microencapsulated ASCs were not osteoinductive. However, we
observed the formation of additional adipose tissue indicating that the ASCs delivered supported
adipogenesis.
A.1 Introduction
The gold standard for bone repair is an autologous source of bone. Autografts have
osteogenic properties and provide structural support for new bone growth, however it is not
osteoinductive. Autografts can be used from the patient’s iliac crest but at least 25% of the patients
still report the experience of pain two years after the procedure. In addition, autografts are
associated with donor site morbidity. An alternative approach for bone formation is growth factors.
BMP2 and BMP7 are Food and Drug Administration (FDA) approved growth factors for bone.
These two members of the BMP2 family achieve bone formation by initiating a cascade of events
resulting in the cells secreting extracellular matrix that is characteristic of bone. Osteopromotive
growth factors such as VEGF and FGF aid in bone formation once the process begins and leads to
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better healing, but by themselves are not osteoinductive. Growth factors can be derived from living
tissue – human or bovine bone, recombinant proteins or gene therapy [95]. To harness the
effectiveness of growth factors the dose, delivery method and release kinetics must be optimized.
Biomaterials induce bone in ectopic sites by initiating a cascade of events resulting in
MSCs undergoing osteogenic differentiation [96]. The roughness, porosity or the chemical
components of the biomaterial are responsible for initiating the cascade of events. The presence of
calcium phosphate has been shown to play an important role in inducing bone [97, 98]. The bone
may form by intramembranous ossification or endochondral ossification if BMP2 is present [97,
99, 100]. The cascade of events involve the chemotaxis of undifferentiated MSCs followed by cell
proliferation. The next steps only occur in the presence of BMP2 - cells are differentiated into
chondrocytes with cartilaginous extracellular matrix; chondrocytes go through maturation,
hypertrophy and calcification; blood vessel and osteoprogenitor infiltration, cartilage removal,
osteoid apposition and bone matrix production; bone marrow formation and bone remodeling [83].
ASCs are multipotent and upon induction with differentiation media, secrete osteogenic
growth factors including BMP2. Therefore ASCs could be used a source of growth factors for
orthopedic tissue engineering. However, ASCs delivered as a suspension will not remain in the
site of delivery. Providing a reliable delivery system, ASCs could be delivered to the site of interest
and aid in the regeneration process by secreting osteogenic factors.
ASCs can be microencapsulated into alginate microbeads as a mode of delivery.
Microencapsulated ASCs remain viable for as long as three weeks. ASCs derived from mice, rats
and rabbits have shown the production of VEGF and BMP2 with and without induction media.
OM treatment with microencapsulated rASCs and mASCs display a reduction in VEGF, however
VEGF production is regained once dexamethasone is removed from OM. rbASCs produced higher
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amounts of VEGF than ASCs from mice or rats. Given the osteopromotive nature of VEGF we
first investigated the ability of microencapsulated rbASCs to induce ectopic bone in male New
Zealand white rabbits. We also investigated the ability of microencapsulated ASCs derived from
mice and rats to induce ectopic bone in athymic nude mice (an American Society of the
Interanational Association for Testing and Materials (ASTM) model) [101].
A.2. Methods
A.2.1 Adipose Derived Stem Cells
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [2, 36], a male New
Zealand rabbit, male C57 Black 6 mice (n=6) under an Institutional Animal Care and Use
Committee (IACUC) approved protocol at the Virginia Commonwealth University. Briefly, the
inguinal fat pad was removed and transferred to a container with Dulbecco’s modified Eagle
medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 3% sterile-filtered L-glutaminepenicillin-streptomycin (P/S). The tissue was washed three times with Hank’s balanced salt
solution (HBSS) (Invitrogen) and then incubated in 0.25% trypsin–ethylenediaminetetraacetic acid
(EDTA) for 30 minutes on a rocker at 37°C. Following trypsinization, the supernatant was
discarded. Adipose tissue was cut into small pieces and incubated in a digestive cocktail containing
collagenase type I (365 units/mL) (Sigma Aldrich) and dispase (3 units/mL) (Gibco, Carlsbad,
CA) for four hours. After incubation, the oily upper layer was removed and the digest was
quenched with an equal amount of MSCGM. The cells were separated, plated in T-175 flasks at
5,000 cells/cm2 and cultured in MSCGM at 37 °C and 5% CO2. For the next two days the
monolayers were washed with Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen) and fed
with MSCGM every 24 hours. Thereafter media were changed every 48 hours and cells were
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cultured to confluence. ASCs were then cultured in either MSCGM, OM or OM without
dexamethasone for an additional seven days before microencapsulation.
A.2.2 Microencapsulated Cells
To form microencapsulated cells, rASCs were encapsulated in UV-sterilized medical grade
alginate (50% mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC
BioPolymer) at a concentration of 10 x 106 cells/ml and crosslinked in a calcium solution. Medical
grade alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a
concentration of 40 mg/ml. Microbeads incorporating cells were created using a Nisco
Encapsulator VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow
rate, nozzle with an inner diameter of 0.12 mm, an electrostatic potential of 6 kV and a calcium
crosslinking solution. The crosslinking solution contained 50 mM CaCl2, 150 mM osmolyte with
15 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 (Sigma Aldrich) (HEPESbuffered) [5, 23]. Alginate microbeads were allowed to crosslink for an additional 10 minutes,
washed with 0.9% (w/v) saline (Ricca Chemical) to remove the excess Ca++, and suspended in the
respective media. Microencapsulated ASCs were cultures overnight in the media they were
previously cultured.
A.2.3 Degradable Alginate Microbead Production
Alginate lyase was incorporated into alginate microbeads by combining equal volumes of
4% medical grade LVM alginate and a 0.9% (w/v) saline containing 0.44 U alginate lyase/ml.
Prior to the combination, both components were kept at 4°C. The final 2% (w/v) alginate was
mixed at 1000 rpm for one minute to produce 0.22 U alginate lyase/g. The alginate/alginate lyase
mixture was used to form microbeads using a crosslinking solution containing 75 mM CaCl2, 90
mM glucose and 10 mM HEPES using the same flow rate, nozzle and electrostatic potential
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described above. The 0.44 U/g alginate mirobeads were made similarly by starting with 0.44 U
alginate lyase/ml solution.
A.2.4 Osteoinductivity of ASCs
6.2.4.1 Rabbit Ectopic Study
rbASCs were cultured in MSCGM or OM for 7 days prior to microencapsulation. Nondegradable (0U/g) and degradable microbeads (0.22 U/g) incorporating these rbASCs were made
on the day before implantation. Microencapsulated rbASCs were loaded into a gelatin capsule and
implanted in the gastrocenmious and rectus femoris of both rabbit legs for 6 weeks.
A.2.4.1.1 Micro CT
All samples were scanned in air using a µCT 40 (Scanco Medical) at 45 kVp, 200 µA, 600
ms integration time, and a voxel size of 35 µm. Images were processed using the accompanying
Scanco medical software. A constant volume of interest representing the absolute volume centered
at the defect cavity was used for the analysis of each sample.
A.2.4.2 Athymic Nude Mice Ectopic Study (osteoinductive nature of microencapsulated rASCs)
rASCs were cultured in MSCGM, OM, or OM without dexamethasone for 7 days before
microencapsulation. rASCs from each treatment group were microencapsulated into nondegradable (0 U/g) and degradable microbeads (0.22 U/g and 0.44 U/g) and stored overnight in
the respective media that incorporated cells treatment. To investigate the osteoinductive potential
of rASCs, microencapsulated rASCs (100 ul) were injected to the gastrocenious of both legs for 8
weeks. In addition, to investigate the time of rASCs release on ectopic bone formation, microbeads
of different release profiles were used.
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A.2.4.3 Athymic Nude Mice Ectopic Study (osteoinductive nature of microencapsulated mASCs)
mASCs were cultured in MSCGM or OM for 7 days prior to microencapsulation. Cells
were microencapsulated into degradable microbeads (0.22 U/g) and stored in MSCGM or OM
overnight. The next day, alginate microbeads were loaded in gelatin capsules with very small
amounts of demineralized bone matrix for 8 weeks.
A.2.5 Histology
After 48 h of fixation in formalin, samples were decalcified for 5 days using .Following
that samples were dehydrated in a series of 95% and 100% ethanol and xylene washes. Samples
were embedded in paraffin, and cut into 8-μm thick sections (Shandon Finesse 325, Thermo
Scientific). The sections were stained with haematoxylin and eosin, and then imaged with a Leica
DMLB microscope (Leica Microsystems, Bannockburn, IL).
A.2.6 Statistics
The results from the in vivo study were calculated as the means ± SEM of both legs of 4
animals per variable thus providing an N or 8 for all studies except the rabbit in vivo study where
an N of was used.. Statistically significant differences between groups were determined by
Student’s t-test. P values ≤ 0.05 were considered significant. Data presented are from
representative experiments.
A.3. Results
A.3.1 rbASCs are not osteoinductive
Demineralized bone matrix, a positive control did not induce ectopic bone (Fig. A.1). Both
degradable and non-degradable microencapsulated rbASCs produced radio-opaque deposits after
6 weeks. Microbeads in the non-degradable groups were present after six weeks with no new bone
tissue present in both GM and OM treated groups The OM pretreated groups produced
significantly higher amounts of radio-opaque tissue. Degradable microbeads were not present after
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6 weeks. Differently stained tissue with a non-muscle morphology was also observed in both GM
and OM groups. None of the samples induced ectopic bone (Fig. A.2).

Figure A.1: H&E staining of DBM implanted in male White New Zealand rabbit after 6 weeks.
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Figure A.2: H&E staining of microbeads in rabbits after 6 weeks, (A) GM treated rbASCs, (B)
OM treated rbASCs microencapsulated in non-degradable alginate microbeads and (C) GM treated
rbASCs, (D) OM treated rbASCs microencapsulated into degradable alginate microbeads.

Figure A.3: Micro CT analysis of osteoinductivity of rbASCs. (A) Volume of radio-opaque tissue.
A.3.2 rASCs are not osteoinductive
DBM induced ectopic bone (Fig. A.4). Non-degradable microencapsulated rASCs were
still present after 8 weeks in all samples across all treatment groups. Although microbeads were
injected in the gastrocnemius, the microbeads were present in other portions of the leg due to the
volume injected compared to the size of the animal’s leg. Non-degradable microbeads did not
induce the formation of ectopic bone.
Degradable microbeads (0.22 U/g) incorporating rASCs, were not present after 8 weeks.
However remnants of the microbeads were present in very small amounts. In the immediate area
of the degraded alginate microbead, tissue with different staining and morphology compared to
muscle was observed, but samples did not induce the formation of ectopic bone (Figs. A.5D –
A.5E).
Degradable microbeads with the fastest cell release (0.44 U/g) also did not lead to any
ectopic bone. Similar new tissue was observed in the muscle with fewer remnants of degraded
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alginate. Nonetheless these microencapsulated rASCs did not induce any ectopic bone. The
different degradation time points did not have any correlation to the volume of new tissue formed.

Figure A.4: H&E staining of DBM implanted in male athymic nude mice after 8 weeks

Figure A.5: H&E staining of rASC osteoinductivity in athymic nude mice after 8 weeks, (A) GM
treated rASCs, (B) OM treated rASCs, (C) OM-d treated rASCs microencapsulated in non-
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degradable alginate microbeads, (D) GM treated rASCs, (E) OM treated rASCs, (F) OM-d treated
rASCs microencapsulated into degradable alginate microbeads (0.22 U/g), and (G) GM treated
rASCs, (H) OM treated rASCs, (I) OM-d treated rASCs microencapsulated into degradable
alginate microbeads (0.44 U/g).
A.3.3 mASCs are not osteoinductive
Regardless of the pre-treatment received, both microencapsulated groups resulted in the
formation of new adipose tissue (Figs. A.6 and A.7). In addition another type of tissue with a nonmuscle or bone-like morphology was also observed directly beside the inactive demineralized bone
matrix. All the degradable microbeads were not present after 8 weeks.

Figure A.6: H&E of mASC osteoinductivity in the gastrocnemius of athymic nude mice after 8
weeks, (A) GM treated mASCs and (B) OM treated mASCs microencapsulated into degradable
alginate microbeads (0.22 U/g).
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Figure A.7: Area of adipose tissue after microencapsulated mASCs were implanted in the
gastrocnemius for 8 weeks.
A.4. Discussion
The demand for osteoinductive materials is always present. Bone induction is achieved by
queues that will lead to the recruitment of MSCs to the local area and subsequent osteogenic
differentiation. The standard for testing the osteoinductive nature of biomaterials is implanting the
biomaterial into the gastrocnemius (a non-bone site) of an athymic nude mice. Microencapsulated
ASCs derived from rat, mouse, rabbit and human are able to secrete osteogenic growth factors
including BMP2 once induced with OM. BMP2 is known to be a potent growth factor in initiating
bone growth. However, other proteins are also important in the formation of bone. One of the
advantages the cell-based approach to bone formation is cells are able to secrete a plethora of
growth factors to aid in bone regeneration. We have quantified BMP2 and VEGF levels secreted
by microencapsulated ASCs derived from four species. Results showed that rabbits were able to
secrete higher total levels of VEGF compared to rASCs. Given the importance of angiogenic
factors in bone formation, we first investigated the ability of microencapsulated rbASCs to induce
ectopic bone. After 6 weeks our histological analysis did not confirm that the radio-opaque tissue
was indeed bone. Although VEGF is important for bone formation it is not the only factor needed.
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In addition, it is possible that a longer time for treatment could be required for rbASCs to induce
bone in vivo. However the formation of new tissue was observed in few samples. This new tissue
was not similar to muscle or bone and would therefore requires additional analysis to determine
the type of tissue formed. In the remaining samples, it is possible that the microbeads were
displaced to other locations of the muscle since the inactivated demineralized bone matrix could
not be located on histological sections.
In addition to VEGF and BMP2, microencapsulated rASCs are known to secrete
ostreocalcin, FGF and osteoprotegerin, all of which are important in bone formation. We have
shown a reduction (not detectable in some cases) in angiogenic factor production once
microencapsulated rASCs were treated with OM. OM-d treatment of microencapsulated rASCs
showed the production of both angiogenic and osteogenic factors, which are both crucial for bone.
Therefore, we investigated the osteoinductive nature of microencapsulated rASCs by using the
ASTM method. After 8 weeks, microencapsulated rASCs previously treated with GM, OM, OMd did not form ectopic bone. This could be due to the quantity of microbeads delivered. It is
possible that a large number of microbeads incorporating cells need to be localized in the same
area, however this was difficult to achieve because of the small muscle size and delivering the
microbeads by an injection. In addition, a longer in vitro culture time may be necessary for the
cells to secrete more growth factors to produce bone.
Having used the ASTM standard to determine the osteoinductive nature of
microencapsulated rASCs which is a xenograft model, we investigated an allograft model using
the ASTM standard by implanting microencapsulated mASCs. At the end of 8 weeks a large
amount adipose tissue was formed. This is not surprising since ASCs were implanted. Even though
mASCS were previously cultured in GM and OM. Similar amounts of adipose tissue was found in
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both groups (Fig. A.7). This indicates that a longer treatment time with OM may be needed to
achieve the desirable results. Studies have shown that mineralization occurs at later time points.
Therefore it is possible that with a longer treatment time ectopic bone could be formed. There was
newly formed tissue around the inactivated demineralized bone. Additional experiments must be
done to investigate whether or not the newly formed tissue is bone and whether it was only due to
the presence of the inactivated bone or delivered ASCs. Some studies have shown that with the
presence of a rough surface alone can encourage new bone formation therefore it is possible that
the inactivated DBM provides a rough surface for the ASCs. In that case the ASCs may need to be
co-delivered with a material that has rough surface.
A.5. Conclusions
Microencapsulated ASCs isolated from mice, rats and rabbits did not form bone
ectopically. Microencapsulated mASCs lead to the engraftment of adipose tissue.
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APPENDIX B

Microencapsulated rASCs Support Osteogenesis in a Unicortical Diaphyseal
Defect

Summary
Bone graft substitutes have been successful in aiding bone regeneration. Recently, it has
been shown that based on the chemical composition, bone graft substitutes can alter the bone
remodeling process and limit the bone marrow cavity regeneration. An alternative approach is to
use cell-based therapies, however their effect on bone remodeling have not been investigated. One
cell-based approach is to deliver microencapsulated ASCs using alginate microbeads.
Microencapsulated ASCs have previously shown to remain viable up to 3 weeks in vitro. In this
study we investigated the effect of microencapsulated rASCs that were previously pretreated with
MSCGM or OM. Degradable and non-degradable microbeads incorporating rASCs were placed
in a 3 mm unicortical diaphyseal defect. Some defects were left either empty or filled with fresh
frozen allograft as a negative or positive control respectively. Our results showed that all defects
healed, both cortical bone and bone marrow were recovered. Samples receiving degradable
microbeads incorporating ASCs that were pretreated with OM produced more bone within the
defect.
B.1. Introduction
Defects in the skeletal system due to injury or disease can be repaired with bone graft
substitutes. Bone graft substitutes usually have one or more of the following components;
osteoinductive proteins that are able to initiate bone formation among the surrounding cells,
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osteoconductive matrix to allow the new bone formed to adhere, and osteogenic cells which have
the ability to form bone [102]. The bone graft substitutes may be autologous, allografts or other
materials comprised of hydroxyapatite, PLGA, tricalcium phosphate, and bioglass amongst others.
An autologous bone graft is normally removed from the iliac crest. This is an excellent solution
but can be difficult to harvest and may be coupled with complications, thus creating a need for
alternative solutions. The bone graft substitutes are typically implanted into the defects which may
be accompanied by external fixation depending on the size of the defect. Once the bone graft
substitute is placed within the fracture a hematoma forms releasing cytokines and growth factors.
An inflammatory reaction occurs to the trauma of the surgery and to the material of the substitute.
This is very important as it leads degranulation and the release of growth factors that will initiate
migration and proliferation of MSCs and fibrovascular tissue in and around the graft. Blood vessels
begin to invade through existing Haversioan or Volkman canals leading to osteocalst resorption of
graft surfaces. Lastly, bone formation occurs on the graft surfaces [12]. Depending on the type of
material, it may contain inherent factors that will to initiate bone growth. Success of bone graft
substitutes have been achieved however previous studies have shown that the chemical
composition is able to inhibit the remodeling of the bone marrow [103]. The bone marrow is
normally remodeled by a series of capillary invasion in the area which carries the MSCs [104].
The main function of the bone marrow is to generate blood cells and store fat. In addition the bone
marrow has many hemapoetic stem cells and mesenchymal stem cells. Therefore without the
presence of the bone marrow the complete function of the bone is not possible.
Another approach to heal fractures is to use cell-based therapies which bring the advantage
of stem cells secreting factors that may be absent at the fracture site or providing additional cells
if the host’s stem cells are not enough. Previously, we have developed a system of
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microencapsulating ASCs into alginate microbeads which allows the cells to remain viable for up
to 3 weeks in vitro. The microencapsulated stem cells have also shown the ability to secrete
osteogenic and angiogenic factors once they are treated with differentiation media. One of the
advantages of this system is that the release of the stem cells can be controlled in a time dependent
manner by using an enzyme known as alginate lyase. This enzyme works by cleaving the
glycosidic bonds. As the cells are released from these microbeads they also maintain their viability
and ability to secrete osteogenic and angiogenic growth factors after induction with differentiation
media.
As a stem cell therapy it is important to determine whether the microencapsulated ASCs
are able to aid in the bone regeneration process and whether or not it inhibits the remodeling of the
bone marrow. Therefore in this study we created a unicortical diaphyseal defect in the femur and
delivered microencapsulated rASCs pretreated with MSCGM, OM, or OM-d for 8 weeks to
determine the effects of this cell-based therapy on osteogenesis and bone marrow remodeling.
B.2. Methods
B.2.1 Adipose Derived Stem Cells
ASCs were isolated from 100-125g male Sprague-Dawley rats (n = 6) [2, 36], under an
Institutional Animal Care and Use Committee (IACUC) approved protocol at the Georgia Institute
of Technology and the Virginia Commonwealth University. Briefly, the inguinal fat pad was
removed and transferred to a container with Dulbecco’s modified Eagle medium (DMEM)
(Invitrogen, Carlsbad, CA) supplemented with 3% sterile-filtered L-glutamine-penicillinstreptomycin (P/S). The tissue was washed three times with Hank’s balanced salt solution (HBSS)
(Invitrogen) and then incubated in 0.25% trypsin–ethylenediaminetetraacetic acid (EDTA) for 30
minutes on a rocker at 37°C. Following trypsinization, the supernatant was discarded. Adipose
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tissue was cut into small pieces and incubated in a digestive cocktail containing collagenase type
I (365 units/mL) (Sigma Aldrich) and dispase (3 units/mL) (Gibco, Carlsbad, CA) for four hours.
After incubation, the oily upper layer was removed and the digest was quenched with an equal
amount of MSCGM. The cells were separated, plated in T-175 flasks at 5,000 cells/cm2 and
cultured in MSCGM at 37 °C and 5% CO2. For the next two days the monolayers were washed
with Dulbecco’s phosphate buffered saline (DPBS) (Invitrogen) and fed with MSCGM every 24
hours. Thereafter media were changed every 48 hours and cells were cultured to confluence. ASCs
were then cultured in either MSCGM, OM or OM without dexametasone for an additional seven
days before microencapsulation.
B.2.2 Microencapsulated Cells
To form microencapsulated cells, rASCs were encapsulated in UV-sterilized medical grade
alginate (50% mannuronate units) (PRONOVA™ UP LVM, ultrapure sodium alginates, FMC
BioPolymer) at a concentration of 10 x 106 cells/ml and crosslinked in a calcium solution. Medical
grade alginate was dissolved in 0.9% (w/v) saline (Ricca Chemical, Arlington, TX) at a
concentration of 40 mg/ml. Microbeads incorporating celwere created using a Nisco Encapsulator
VAR V1 LIN-0043 (Nisco Engineering AG, Zurich, Switzerland) at a 5 ml/hr flow rate, nozzle
with an inner diameter of 0.12 mm, an electrostatic potential of 6 kV and a calcium crosslinking
solution. The crosslinking solution contained 75 mM CaCl2, 90 mM osmolyte with 10 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 (Sigma Aldrich) (HEPES-buffered) [5].
Alginate microbeads were allowed to crosslink for an additional 10 minutes, washed with 0.9%
(w/v) saline (Ricca Chemical) to remove the excess Ca++, and suspended in the respective media.
Microencapsulated ASCs were cultures overnight in the media they were previously cultured.
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B.2.2.1 Degradable Alginate Microbead Production
Alginate lyase was incorporated into alginate microbeads by combining equal volumes of
4% medical grade LVM alginate and a 0.9% (w/v) saline containing 0.44 U alginate lyase/ml.
Prior to the combination, both components were kept at 4°C. The final 2% (w/v) alginate was
mixed at 1000 rpm for one minute to produce 0.22 U alginate-lyase/g alginate. The
alginate/alginate lyase mixture was used to form microbeads using a crosslinking solution
containing 75 mM CaCl2, 90 mM glucose and 10 mM HEPES using the same flow rate, nozzle
and electrostatic potential described above.
B.2.3 Unicortical Diaphyseal Defect
To determine if microencapsulated rASCs would prevent the remodeling process
microbeads were placed in a unicortical defect for 8 weeks. A defect was created on the proximal
portion of the femur with a trephine (3 mm inner diameter). To reduce the blood flow from the
marrow cavity, pressure was applied using gauze to the newly created defect before implanting
microbeads in the defect.
B.2.4 Histology
After 48 h of fixation in formalin, samples were decalcified for 5 days using .Following
that samples were dehydrated in a series of 95% and 100% ethanol and xylene washes. Samples
were embedded in paraffin, and cut into 8-μm thick sections (Shandon Finesse 325, Thermo
Scientific). The sections were stained with haematoxylin and eosin, and then imaged with a Leica
DMLB microscope (Leica Microsystems, Bannockburn, IL).
B.2.5 Histomorphometrics
A region of interest around the defect was chosen or all samples. The area of connected
cortical bone was measured and unconnected bone in the marrow cavity was also quantified as
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trabecular bone. The remaining area within the bone marrow was quantified as bone marrow
cavity.
B.2.6 Statistics
The results from the in vivo study were calculated as the means ± SEM of both legs of 4
animals per variable thus providing an N or 8. Statistically significant differences between groups
were determined by Student’s t-test. P values ≤ 0.05 were considered significant. Data presented
are from representative experiments.
B.3. Results
B.3.1 Both bone marrow and cortical bone were recovered
Defects that were not filled with microbeads (empty) during surgery healed within 8 weeks
with both cortical and bone marrow recovering. The application of fresh frozen allografts to defects
resulted in cortical bone recovery in 7 of 8 samples, however the bone marrow was not fully
recovered in most samples where pieces of allograft were still remaining after 8 weeks.

Figure B.1: H&E staining of the defect site in the femur after 8 weeks.
Non-degradable microbeads as expected were present after 8 weeks in the cortical bone,
bone marrow cavity, and area directly outside of the defect (opposite to the marrow cavity). In
non-degradable groups, all samples healed with both cortical bone and bone marrow recovering
clxv

independent of rASC pretreatment. In the cortical and trabecular bone, bone formed around the
microbeads making complete contact with the microbead’s surface.
Degradable microbeads were not present within the defects after 8 weeks. All the defects
healed completely with one sample either in the GM and OM group generating additional bone
attached to the femur. Microbeads were not present after 8 weeks and no indications of an
inflammatory response. The area of new bone in the defect site was significantly higher in the OM
group compared to the empty.

Figure B.2: H&E staining of unicortical defects receiving non-degradable microencapsulated
rASCs pretreated with A) GM, B) OM, C) OM-d or degradable microencapsulated rASCs
pretreated with D) GM, E) OM, F) OM-d after 8 weeks.
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Figure B.3: Histomorphometric analysis of (A) cortical bone (B) trabecular bone and (C) marrow
cavity of the unicortical diaphyseal defect after 8 weeks.
B.4. Discussion
Therapies for fractures or non-unions have the primary goal of facilitating bone
regeneration without inhibiting the bone remodeling process. Previously, it has been shown that
the chemical composition of bone graft substitutes can inhibit the bone remodeling process by
delaying the marrow recovery [103]. Stem cells are multipotent and can be delivered in vivo by
using alginate microbeads. The paracrine effect of growth factors produced by stem cells can be
used to facilitate bone regeneration. This cell-based therapy involves alginate microbeads, ASCs
and alginate lyase for degradation. However the effects of alginate lyase and the by-products of
alginate lyase mediated degradation on bone remodeling are known. As this cell-based therapy is
developed it is important that it does not inhibit the bone remodeling process. Therefore we
investigated the effect of microencapsulated rASCs on bone remodeling.
The results showed that microencapsulated rASCs did not inhibit the bone remodeling
process. All non-degradable sample as healed well more importantly newly formed bone was able
to form around the alginate microbeads indicating that the surface of alginate beads are
osteoconductive. There was also a trend of more bone being present in the samples compared to
empty defect which may be due to the growth factors secreted by encapsulated stem cells.
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Naturally derived hydrogels have been used for bone repair due their biocompatibility and
tunability. The mechanical properties of these hydrogels are not well suited for bone.
All samples receiving degradable alginate microbeads healed well and reflected a similar
trend of more bone being present within the region of interest. The osteogenic media pretreated
groups produced more bone which could be due to the cells differentiating along the osteogenic
path and enhancing the bone healing. In one sample extra bone was present in the GM and OM
group. This may have resulted from the factors secreted from the encapsulated cells localizing in
the area just outside the defect and initiating bone formation.
B.5. Conclusions
Microencapsulated ASCs supported osteogenesis and did not alter the bone remodeling
process. The alginate microbeads were able to deliver the cells and their secreted factor to the area
however they did not alter the bone remodeling process.
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